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Abstract
The thesis has three related parts, two modeling studies to investigate the 
chemical properties of oxidative spiroannulations and a third part using the 
information learned from the two modeling studies to induce facial 
diastereoselectivity for the formation of a m-C7N unit analogue for manumycins. 
The 1st modeling study, involved the selective tosylation of the amino functional 
group on (L)-tyrosine and its subsequent spiroannulation. The 2nd part of the 
thesis, deals with an electron-donating functional group on various starting 
materials for the spiroannulations of racemic analogues of manumycins, (+/-)- 
75/76, and the effect the electron-donating group has on spiroannulations.
OH O H
NO,
CHO
O V
O
4-hydroxy-3-nitrobenzaldehyde (+/-)-75 /  76
The final part of the thesis entailed starting with a compound from the 
chiral pool, (L)-3-nitro-tyrosine, which we were able to use to synthesize 
compound (+)-79 in five steps from the starting material, with a 3:1 ratio of
ii
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diastereoselectivity at the spirocarbon (total isolated yield of 85 %). Compound 
(+)-79 represents the facial selective formation of a para-quinol analogue and is 
two steps away from being a m-C7N unit analogue for manumycins.
OH
Ts-HN,
OH Ts-HN
V
o
67 (+) -79
+
Ts-HN
80
V
o
iii
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Chapter 1
Introduction
(1.1) General
In nature, there is a conservation of oriented structural elements in three- 
dimensional organic compounds. A consequence of this conservation is that the 
amino acids and sugars which form proteins and carbohydrates, predominately 
favour one stereoisomer called an enantiomer. Enantiomers are molecules which 
are non-superimposable mirror images of each other, due to the molecules’ 
structural elements oriented in a specific left or right handed order in 3- 
dimensional space around a central atom. The central atom of such a compound is 
said to be the chiral centre for the molecule and this chiral property of an 
enantiomer molecule is referred to as its chirality. Thus, these qualities of amino 
acids and sugars provide for the conservation of chirality throughout biological 
polymers that make up all living matter. As a consequence, metabolic or 
regulatory processes controlled by biological systems can be sensitive to a 
stereospecific enantiomer and this sensitivity is often a unique feature of 
enzymatic reactions and metabolic processes.1 The degree of sensitivity to a pair of 
enantiomers is such that often there is a more active enantiomer (eutomer) for a 
given action of interest, while the other enantiomer (distomer) can have a wide 
range of varying actions. The possible range of actions for the distomer can 
include having: partial biological activity, no biological activity, different rates of
1
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metabolism, or being antagonistic to the original eutomer’s biological activity, or 
having a different biological activity all together, that is either desirable or 
undesirable.2
The paradigm shift caused by the advance in stereoselective bioanalysis and 
stereoselective technologies in the 1980s has led to this new awareness of the 
sensitivity of biological processes to enantiomers. Previously, racemic compounds 
(an even mixture of enantiomers) have dominated the pharmaceutical industry. 
However, when considering the possible different biological effects that eutomers 
and distomers have, it is clear that using enantiopure drugs has had major 
advantages. These advantages and disadvantages contributed to regulatory 
controls being established with the publication of formal guidelines in a document 
entitled Policy Statement fo r  the Development o f New Stereoisomeric Drugs in 
1992 by the United States.3 The European Union followed the United States’ lead 
in 1994 with similar guidelines in the document Investigation o f Chiral Active 
Substances.4 Essentially, all applicants seeking drug approval must now recognize 
the occurrence of chirality in new drugs. Attempts must be made to separate the 
enantiomers and evaluate each stereoisomer’s contribution to the perceived 
medicinal benefits of the substance. The benefits of the enantiomers are then 
examined individually or together as a racemic mixture in order to make a rational 
selection of the stereoisomeric form that is to be marketed.2
Worldwide sales of enantiopure drugs continue to increase at significant 
rates. For example, in 1996 there was a 27% (US $ 74.4 billion) increase of
2
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enantiopure compounds marketed. This trend has continually increased each year 
to an impressive 39 % (US $151.9 billion) in 2002.2
Many of the new enantiopure pharmaceuticals are the result of research 
examining compounds isolated from natural products. The isolated natural 
compounds are subjected to a series of broad based screenings for biological 
activity to determine the compound’s biological worth. As a continuation of this 
process organic chemists use three broad research streams in order to increase the 
biological activity of potential lead compounds: (1) using the natural product to 
build new analogs and derivatives, (2) the diversity-orientated synthetic route to 
new skeletons, and (3) creating new derivatives based upon paths made available 
by total synthesis of the natural product.5
The approach used in this thesis was based on the third research method, 
thus, creating new derivatives based upon paths made available by the total 
synthesis of the natural product. But instead of using total synthetic routes already 
established, the primary goal of the research presented here was to develop a novel 
stereoselective route to new natural product analogues of the manumycin family.
(1.2) Manumycins
The manumycin family of compounds are a class of secondary metabolites 
isolated from microbial origins that, presently, consist of 28 similarly structured 
molecules.6’7 The term for this class of compounds originated from Manumycin A 
1, (previously called Manumycin), the first member of this family of compounds
3
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isolated by Zahner and co-workers in 1963. In 1973, Schroder and Zeeck 
proposed a novel structure for Manumycin A 1 but the stereochemistry was later 
revised by Taylor and co-workers after they reported their synthesis of the 
enantiomer of the natural product.8 The common structural elements used to 
classify manumycins are: two unsaturated carbon chains, attached meta-fashioned 
to a distinctive functionalised cyclic core (see Figure l).9
The distinctive cyclic core of manumycins, often referred to as an m-C7N unit, can
o  ^  9 H3 c h 3  c h 3
Type I m-C7N unit Upper or Eastern Chain
O c h 3 c h 3  c h 3
1 Manumycin A
Type II m-C7N unit
Lower or Southern Chain
C5N unit
2 Manumycin D
Figure 1 Structural elements of Manumycin 
A and Manumycin D 11
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exist as either a type I or a type II configuration. The type I configuration has an 
oxirane at the C-5/C-6 carbons of the cyclic core m-C7N unit, while the type II 
configuration has a hydroxylethylene at the C-5/C-6 carbons of its m-C7N unit, as 
illustrated in Figure 1 with Manumycin A 1 (type I) and Manumycin D 2 (type II) 
respectively.10,7 Another common feature to many of the manumycins is a 2- 
amino-3-hydroxycyclopent-2-enone moiety (C5N unit) linked to the “lower” or 
“southern” chain as shown in compound 2. While the family of manumycins retain 
many similar structural elements, the significant structural differences between 
manumycins occur mostly in the “upper” or “eastern” chain. These structural 
variations of the “upper” chain involve different patterns of methyl branches and 
double bonds with varying lengths of polyunsaturated carbon chains attached to 
the m-C7N unit. 11 (For a complete table of Manumycins see Appendix 2).
(1.3) Origin of Manumycins
All manumycins come from micro-organisms isolated from soil samples 
collected worldwide.11 The micro-organisms are taxonomically characterized as 
actinomycetes (genus: Streptomycetes), gram positive, mycelical, and sporulating 
bacteria. The specific properties which have characterized manumycins’ discovery 
during natural product research are antibacterial and/or the inhibition of the two 
enzymes farnesyltransferase or interleukin-1 (3. Typically, the different types of 
bacteria producing manumycins are cultivated using the standard procedures for 
Streptomycetes strains. The manumycins can then be isolated from either the
5
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culture filtrate or the mycelium. Isolation of the compound is accomplished with 
standard procedures involving organic solvent extraction techniques of the culture 
filtrate or the mycelium, followed by purification using column chromatography 
on silica gel or reverse phase (RP) silica gel. One other separation technique 
sometime utilized for the purification of manumycins is gel-permeation 
chromatography on Sephadex®LH-20.12
(1.4) Biosynthetic Pathways of Manumycins
Researchers have attempted to determine the biosynthetic pathways of 
manumycins using the first two manumycins discovered: Manumycin A 1 and 
Asukamycin13 (see structure in Appendix 2). The technique used to determine the 
biosynthetic building blocks of the bacteria’s pathways involves feeding studies 
using stable radioactive isotope-labelled precursors fed to the bacteria. 1315 
Currently, the formation order or mechanism of the building blocks that make the 
m-C7N unit is unknown. 13 The m-C7N unit is believed to come from combining a 
four carbon dicarboxylic acid derivative, like succinate or oxalacetate, with one 
molecule of a glycerol metabolite. While the epoxides and hydroxyl functional 
groups of the m-C7N unit are known to come from molecular oxygen, the carbonyl 
functional group does not come from molecular oxygen. The nitrogen of the m- 
C7N unit is believed to have come from somewhere within the nitrogen pool. But 
once the m-C7N unit is formed, bacteria then initiates the assembly of the “lower” 
chain in both compounds using three malonyl-CoA substituents. The C5N unit at
6
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the end of the chain comes from an intramolecular cyclization of 5-aminolevulinic 
acid. The “upper” chains’ cellular pathways appear to be assembled differently for 
Manumycin A 1 and Asukamycin; however, both come from a polyketide origin. 
These differences in the “upper” chain cellular pathways should not be surprising
considering that this is where most structural differences in the manumycin
1 ^secondary metabolites are found.
(1.5) Biological Activity of Manumycins
The manumycins show many interesting biological properties in vitro and 
in vivo which so far include: antibiotic, antifungal, antiparasitic, anticoccidial, 
trypanocide, and insecticidal activites.11 Manumycins’ biological properties have 
led to a number of patents being issued for their various applications and possible 
economic potentials.
Another biological activity manumycins possess is the ability to inhibit 
enzymes in plants and animals. The inhibition of plants enzymes could possibly 
lead to treatments to help alleviate drought by Manumycin A ’s 1 ability to regulate 
the stomata openings in plants. In humans, the inhibition of certain enzymes could 
conceivably be used in potential cancer therapies.
(1.5.1) Antibacterial Activity of Manumycins
Manumycins with the structural type I m-C7N configuration display 
antibacterial activity to gram positive bacteria.16 However, manumycins with the
7
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structural type II m-C7N configuration do not exhibit any antibacterial properties. 
This difference could lead one to suggest that the epoxide on the m-C7N unit is a 
necessary component of the manumycins antibacterial properties. Some of the 
gram positive bacteria tested with various manumycins include: 11 different types 
of Staphylococcus with a minimum inhibitory concentration (MIC) range of 0.39- 
16 micrograms per millilitre (pg m L _1), 2 different types of Streptococcus 
faecalis with a MIC of 6.4 (pg mL -1), 3 different types of Micrococcus with a 
MIC range of 0.39-16 (fig mL -1 ), and 9 different types of Bacillus with a MIC 
range of 0.19-12.5 (jpg mL _1) .1619
Most of the manumycins tested did not inhibit gram negative bacteria 
growth. Surprisingly, Manumycins E, F and G did inhibit a gram negative 
bacteria, demonstrating a MIC range of 0.1-2.5 (pg mL -1 ) for Escherichia coli 
SGB888.16 19 The biological manner in which manumycins inhibit both types of 
bacteria in vitro is not known and, to date, no drug resistant bacteria have been 
tested. However, due to their prohibitive costs, manumycins are not currently ideal 
candidates for antibiotic applications. As of May 2004, the cost of Manumycin A 
was: 1 milligram (mg) US $ 40.00, 5 mg US $ 120.00, and 10 mg US $ 190.00, 
from A.G. Scientific, Inc.20 However, there have been a number of patents issued 
for various manumycins and their derivatives which have also included their 
antibiotic properties. Some examples of these patents are for the compounds
/ } f  /yn •y'l
Asukamycin , Alisamycin , Manumycin C, Manumycin D, Manumycin E , 
and for manumycin type epoxycyclohexenedione derivatives.24’25
8
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(1.5.2) Antifungal Activity of Manumycins
The extensive use of fungicides worldwide is a serious environmental 
concern and has concurrently increased the number of resistant strains of fungi.26 
However, antibiotics derived from microbial origins generally have fewer 
environmental side effects and show little toxicity towards the host plant. The 
microbial antibiotics also have selective inhibitory activity and are able to 
decompose quickly, thus lessoning their environmental impact. Presently, there 
are manumycins and manumycin derivatives that have exhibited antifungal 
activity for a number of different fungi.26 The fungus Candida albicans is 
inhibited by Manumycin A 1 (MIC 21 jag mL -1) 9, Alisamycin (MIC 10 jag mL _1) 
19, two benzoquinone derivatives of Manumycin B (MIC 10 jag mL _1) and 
Manumycin C (MIC 42 jag mL _1) 27 Asukamycin was reported to have a weak 
antifungal activity against Trichophyton mentagrophytes at a moderate
 1 1 o
concentration (MIC 25 pg mL ). Another manumycin derivative, SW-B 
(2,4,6,-trimethyldeca-(2E,4E)-dienamide), an amide composition of the upper 
chain of both Manumycin A 1 and Manumycin D 2, showed a high level of 
inhibitory activity against P. capsici, M. grisea, C. cucumerinum, and M. grisea. 26 
Hyphal growth of the pervious fungi were inhibited by more than 50% at a level of 
10 pg mL and by about 90% at 50 pg mL _1 . Further research with 
manumycins may help produce new fungicides treatments that address the 
environmental concerns due to excessive applications of broad range fungicides.
9
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(1.5.3) Antiparasitic Activity of Manumycins
Eimeria belongs to the phylum Apicomplexa and is closely related to the 
infamous parasites Plasmodium, Toxoplasma and Cryptosporidium. Plasmodium 
is the causative agent of the disease malaria, and Toxoplasma is an opportunistic 
parasite associated with AIDS and some congenital birth defects. Cryptosporidium 
is a worldwide waterborne parasite causing severe diarrhoea. Eimeria are 
intracellular protozoan parasites that can cause significant disease and death 
among cattle and poultry, thus inflicting severe economical hardship on those 
industries. Specifically, Eimeria tenella develops within epithelial cells that line 
the intestinal tract of domestic fowls and likely infects 30 billion chickens 
annually.28 When Asukamycin was added to the feed (at 100 parts per million 
(ppm)) of 4 day old chickens infected with Eimeria tenella, it was found to 
inhibit coccidial activity in their intestines.18
Trypanosoma brucei, another parasite found mainly in Eastern and 
Southern Africa, is spread by the blood sucking Tsetse fly and is the cause of 
“sleeping sickness” in humans. Unfortunately, prospects for a vaccine against the 
parasite are low, and more worrisome, is the fact that the parasites are starting to 
develop resistance to the compounds presently used to combat them.29 A number 
of farnesyltransferase inhibitors were tested for their efficacy against 
Trypanosoma brucei. Surprisingly, only Manumycin A 1 and a number of racemic
o n
quinone manumycin analogues were effective against the parasite. The racemic
10
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analogues being tested had the structural features of Manumycin A 1 but, 
surprisingly, the researcher did not explore if there were any possible differences 
in enantioselective efficacy. While Manumycin A 1 and the quinone analogues 
inhibited the growth of the parasites in both the vertebrate’s bloodstream and the 
procyclic form within the Tsetse flies, it was not just the famesyltransferase 
inhibiting action that affected the parasites. A post morphological analysis showed 
there was significant mitochondrial damage within the parasite. Further testing 
indicated that Manumycin A 1 also affects the mitochondria of mammalian cells in 
a similar way, but to a much lesser degree.30 A patent (in January 2001) was issued 
for the properties of manumycin A and manumycin type analogues as an 
application to treat or prevent numerous parasitic disorders by the World 
Intellectual Property Organization (WIPO).31
(1.5.4) Insecticidal Activity of Manumycins
Manumycin A 1 was tested for its efficacy as an insecticide agent against 
Lepidoptera (butterflies and moths) and Coleoptera (beetles).9 By applying an 
aqueous solution of Manumycin A 1 (0.05 %) to the vulnerable plants,
Manumycin A 1 acted as an insecticidal development restrictor on the eggs and 
larvae of Pieris brassicae (cabbage white butterflies) and Epilachna varivestis 
(Mexican bean beetles). After the initial application, a repellent effect was also 
observed on larvae intending to feed on the same plants treated with Manumycin 
A 1. Unfortunately, higher concentrations of Manumycin A 1 did not increase the
11
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efficacy of the insecticide and was slower to work than a comparable chitin 
synthase inhibitor.
(1.5.5) Plant Enzyme Inhibition by Manumycins
Stomata are pores found on the outer layer of the aerial parts of most plants. 
The stomatal opening of the plant is used to regulate the gas exchange between the 
atmosphere and the interior of the plant. Therefore, the opening and closing of the 
stomata influences two important processes of vegetative plants: (1) 
photosynthesis with the uptake of C 0 2 and (2) transpiration with the evaporation 
of water. Plants lose over 90 % of their water through transpiration. The phyto­
hormone abscisic acid prevents this water loss by closing the stomatal aperture via 
the guard cells. It has been discovered that this process can be regulated through 
the inhibition of famesyltransferase using Manumycin A 1. Thus, Manumycin A 1 
or a Manumycin derivative could be utilized as a means to enable plants to better 
survive droughts.33 Currently, a patent application is being reviewed by the WIPO, 
which proposes using the inhibition of famesyltransferase as an application to 
control the effects of droughts on plants.34
(1.5.6) Inhibition of Enzymes by Manumycins
The first mammalian enzyme activity describing manumycins was the 
inhibition of the human polymorphonuclear elastase by Manumycin A 1 with an 
inhibitory concentration of 50 % inhibition (IC50 ) = 4.0 /ig m L'1.35 The secretion
12
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of elastase by tumour cells to destroy elastin (a protein responsible for the 
elasticity of body tissues) is important in the processes of tumour cell invasion and 
the metastasis of tumours.
In 1993, during yeast based screening assays, Manumycins A 1, B, C and 
their benzoquinone analogues were discovered to be inhibitors of Ras
on o.f\famesyltransferase. ’ Manumycins A 1, B, C have an IC50 = 5, 13, 7 micromolar 
(fiM.) respectively for the inhibition of Ras famesyltransferase. Part of the study 
examined the benzoquinone analogues of manumycins A 1, B and C that lack the 
“lower” side chain. It is important to note the lack of the “lower” side chain did 
not significantly reduce inhibitory activity of the benzoquinone analogues. The 
Ras famesyltransferase enzyme is known to activate the Ras proteins by 
transferring a famesyl residue from famesyl diphosphate to a sulphur atom of the 
cysteine amino acid on the Ras protein. This is the first of four steps involved in 
the post-translational modification needed to activate many Ras proteins. Once the 
four modifications take place on the Ras proteins, the Ras protein attaches 
covalently to the inner cell membrane and act as relay signals from the cell 
surfaced receptors to the nucleus. It is through control of this cellular pathway that 
cell proliferation is stimulated and regulated.
The superfamily of Ras proteins are currently being studied because of their 
role in cell growth and their suspected association with 30 % of all cancers.37 In 
mammalian cells there are three types of Ras proteins: H-Ras, K-Ras, and N-Ras 
proteins.38 In at least 17 different types of cancer, mutated Ras proteins have been
13
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isolated and identified. These mutant Ras proteins are suspected to be a factor in 
the malignant growth of solid tumours in 90% of pancreatic cancers, 50% of colon
OQ
cancers, and 30% of lung cancers.
Ras proteins were originally named after the ras gene, which was first 
identified in viruses that caused rat sarcoma.40 Researchers have speculated that 
mutated Ras proteins are believed to come from ras oncogenes that have been 
incorporated into organisms by viruses. Once incorporated in the organism, they 
are thought to be conserved through evolution in organisms as divergent from 
humans to yeast40
During further in vitro screenings, manumycins were found to inhibit 
caspase-1, also called interleukin-1 p converting enzyme (ICE).35,41 Interleukins 
are produced by immune system cells such as lymphocytes, macrophages and 
monocytes. Interleukins are regulatory proteins that are members of the larger 
family of cytokines. Cytokines control inflammation and immunity by regulating 
both growth and differentiation of lymphoid and other cells. ICE has been 
suspected of being involved in acute and chronic inflammation. The Caspase 
family of protein enzymes are linked to the regulation of inflammation and 
programmed cell death (apoptosis). Caspase-1 and Caspase-11 regulate and 
control inflammation while the other 11 mammalian caspases are believed to 
initiate and control apoptosis. During the in vitro screening, eight manumycins and 
a few of their benzoquinone analogues exhibited inhibitory activity towards 
caspase-1, with the manumycin EI-1511-3 (see Appendix 2) demonstrating a
14
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notable IC50 = 90 nanomolar (nM) of inhibitory activity.35,41 Hence, manumycins 
or their analogues could become a prospective treatment for various inflammatory 
diseases.
Additional research has uncovered a number of other enzymes that are also 
inhibited by manumycins. Manumycins and their benzoquinone analogues are 
irreversible inhibitors of neutral sphingomyelinase 42 Sphingolipids were long 
considered to be inert lipids of cell membranes, but have recently been shown to 
have roles in cell biology and signal transduction.43 Sphingolipid ceramide is 
regulated by the sphingomyelinase enzyme and plays a pivotal role in the 
sphingomyelin cellular pathway 43 Ceramide is a regulated product of this 
pathway and is thought to trigger and/or control proliferation, differentiation, 
growth arrest and apoptosis in cells. Recent studies strongly suggest that ceramide 
plays a vital role in inflammations and tumour suppression. Further research in the 
sphingomyelin cellular pathway may help produce new therapeutic treatments 42
(1.6) Investigation of Manumycins for Medicinal Properties
Recent advances in biochemistry and genetic research on the complexities 
of biological processes within the cell has afforded the development of new 
methods to combat previously incurable diseases 44 However, the need for new 
therapeutic agents is evident from our limited success with the treatment of so 
many diseases. As our understanding of the intricate cellular pathways within the 
cell increases, we are able to manipulate a number of pathways through inhibitors
15
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with increasing success. One of the cellular pathways currently under investigation 
is the use of Ras famesyltransferase inhibitors as potential therapeutic agents.44
(1.6.1) Inhibition of Corneal Inflammation by Manumycins
Corneal inflammation can result from numerous types of eye injuries and 
medical procedures on the eye 45 While Ras famesyltransferase inhibitors are 
generally considered as potential anticancer drugs, 44 their ability to inhibit 
inflammation has also been documented.35,41,42,45 A study looking at two Ras 
famesyltransferase inhibitors tested mice with corneal inflammation, that were 
induced by cauterization to the eye of each mouse, for the efficacy of the two 
compounds.45 Manumycin A 1 and Gliotoxin were each dissolved in a 1 mM 
balanced salt solution containing 0.1 % Dimethyl Sulfoxide (DMSO). The 
inhibitors were then tested by applying the solution topically every 8  hours onto 
the eye with the induced corneal inflammation. It was found that these inhibitors 
have good therapeutic potential in inhibiting corneal inflammation that was 
induced by cauterization. As well, the study found that the two inhibitors 
selectively inhibited the macrophages at the cauterized cornea. Furthermore, 
Manumycin A 1 and Gliotoxin did not exhibit any discernible side effects on the 
cornea of the control mice used in the study 45
16
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(1.6.2) Inhibition of Brain Tumours
At the University of Saskatchewan, researchers Wang and Macaulay 
compared the efficacy of Manumycin A 1 to Lovastatin on medulloblastoma cells 
in vitro.46 Medulloblastoma is a malignant cerebellar tumour usually found in the 
brain of children 3 to 8 years old. Lovastatin is a competitive inhibitor of 3- 
hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA), that previously exhibited 
inhibitory activity to medulloblastoma cells. Lovastatin induced cell apoptosis 
usually required 36 to 96 hours of treatment and caused cell cycle arrest. Whereas, 
the cells treated with Manumycin A 1 did not cause cell cycle arrest and cell 
apoptosis required only 12 to 24 hours of treatment. The authors of the study also 
questioned the importance of Ras inhibition in cell apoptosis when using 
Manumycin A 1. As the authors noted, once Ras proteins are maximally inhibited 
by 10 pM of Manumycin A 1, cell apoptosis can be increased by the addition of 
more Manumycin A 1. They speculated that the inhibitor might be causing cell 
apoptosis through other biological pathways unrelated to Ras famesylation .46
(1.6.3) Multiple Myeloma
Multiple Myeloma is a haematopoietic (formation of blood or blood cells) 
malignancy arising from the formation of blood plasma cancer cells (myeloma 
cells) that tend to collect in bone marrow .47,48 When the myeloma cells collect at 
one site in a bone and form a tumour, it is called a plasmacytoma. Unfortunately, 
in most cases the myeloma cells collect in multiple sites on bones throughout the
17
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body forming many plasmacytomas and this condition is called Multiple 
Myeloma. It is also important to note that there is a fine distinction between 
Multiple Myeloma and bone cancers. Multiple Myeloma is a cancer of the blood 
plasma immune cells that begin within the immune system but express tumours in 
bones; primary bone cancer instead starts within the bone. Multiple Myeloma is 
regarded as incurable and has demonstrated a strong resistance to standard 
chemotherapeutic strategies.
Researchers in Italy discovered the Interleukin-6  enzyme plays an 
important role in drug resistant myeloma cells.47 The enzyme activates several 
cellular pathways for proliferation in opposition to the chemotherapeutic 
treatment. It was also noted that 40 % of Ras proteins in new Multiple Myeloma 
patients were mutated and as the disease progresses the amount of mutated Ras 
proteins also increased. In vitro treatments of myeloma cells with Manumycin A 1 
stopped cell proliferation and induced cell apoptosis. Further analysis linked over 
expressed activation of caspase-3, an enzyme link to the cellular pathway of cell 
death, with the manumycin induced apoptosis. These results establish potential 
opportunities for additional research for a chemotherapeutic treatment of the fatal 
disease Multiple Myeloma.47
(1.6.4) Lung Tumours
In a study to test the efficacy of a number of Ras famesyltransferase 
inhibitors on lung cancers, surprising results occurred when using manumycin A
18
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I .49 The study comprised two parts: an in vivo part against a lung tumour model in 
mice and an in vitro part involving four tumour cell lines. The in vivo evaluation 
of manumycin A 1, gliotoxin, and dihydroepiandrosterone (DHEA) in the mice 
tumour model, showed the compounds increased tumour growth over the control 
mice in the study. Manumycin A 1 inhibits all four cell lines in vitro with an 
effective dose of 50% (ED50) at a 4-6 /iM concentration. However, further testing 
in vitro demonstrated that when an insufficient concentration of manumycin A 1 
was used (lpM ), 3 of the 4 tumour cell lines are instead stimulated by 10-13 % 
more growth than the control cell line. Similar results were observed for the other 
two Ras famesyltransferase inhibitors, gliotoxin and DHEA. The authors of the 
study speculated that perhaps the treatment in vivo may have increased a non-ras- 
dependent pathway for tumour growth when the effective concentration is too 
low 49
(1.6.5) Pancreatic Cancer
Pancreatic cancer is still resistant to most chemotherapeutic treatments and 
is the 5th leading cause of cancer death in the United States. Long term survival is 
only seen in patients who undergo complete resection of the localized tumour. A 
number of studies with manumycin A 1 have been undertaken to evaluate its 
efficacy in treating pancreatic cancer.50'53 Pancreatic cancer is known to have a 
high (> 90 %) proportion of mutant K-Ras proteins. An in vitro study using human 
pancreatic cancers cells (SUIT-2, MIA PaCa-2, AsPC-1, BxPC-3) revealed that
19
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manumycin A 1 inhibited all four types of pancreatic cancer cells in a dose- 
dependent manner. When the cancer cells were inoculated into nude mice, 
manumycin A 1 again inhibited tumour growth and also liver metastasizing 
cells.51’52
Presently, chemoradiotherapy is often used in the treatment of pancreatic 
cancer as it offers a slight improvement in the patient survival rates compared to 
other forms of treatment.53 Manumycin A 1 was evaluated for increasing the 
radiosensitivity of pancreatic cancer xenografted onto nude mice. The results 
indicated that there is a substantial benefit for treating pancreatic cancer when 
incorporating Manumycin A 1 into chemoradiotherapy treatment.53
(1.6.6) Liver Cancer
Hepatocellular carcinoma is one of the most common lethal cancers in the 
world.54'56 Presently, this liver cancer has no effective treatment and patients’ 
long term survivability is poor and new therapies are badly needed. It previously 
has been reported that Hepatocellular carcinoma has N-Ras protein mutations and 
therefore, researchers investigated using Manumycin A 1 as a potential therapeutic 
agent. All three studies substantiated that Manumycin A 1 has an inhibitory affect 
in vitro and elicits the induction of apoptosis in HepG2 cells. Further analysis in 
the studies revealed that the HepG2 cells underwent DNA fragmentation after only 
12 hours of treatment with manumycin A 1. During induction of cell apoptosis by 
manumycin A 1 , p53 (a tumour suppressor protein) and p21WAF1 (works
20
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concurrently with p53) expression was increased. Also, the activation of caspases 
(the enzymes involved in cell death) and the inhibition of the NF-kB pathway (a 
defensive response mechanism pathway to stresses) were noted in the HepG2 
cancer cells after treatment. The studies concluded that the use of manumycin A 1 
shows potential as an effective treatment against hepatocellular carcinoma.54’56
(1.6.7) Colon Cancer
Various studies investigating the use of Manumycin A 1 in the treatment of 
colon cancer determined that the Ras famesyltransferase inhibitor caused cell 
apoptosis in a number of different colon cancer cell lines.57’59 In the colon cancer 
cell line LoVo, Manumycin A 1 exhibited a dose dependent inhibition of the 
cancer cells’ proliferation in vitro. Further analysis showed that Manumycin A 1 
also inhibited DNA synthesis.57
For the human colon cancer cell line COLO320-DM, which does not 
contain a mutant Ras protein, Manumycin A 1 was evaluated for its biological 
activity.58 Manumycin A 1 was demonstrated to be cytotoxic to COLO320-DM 
cancer cells in vitro. The study also suggested that cell apoptosis is a result of the 
inhibition of the p2 1 ras farnesylation, which reduced signal transduction through 
the p42MARK/ERK2 pathway (the p42MARK/ERK2 pathway is involved with 
growth factors of cells). The authors also noted that for cancer cells with non­
mutant Ras proteins, less Manumycin was needed for cell apoptosis than when 
compared to studies with cancer cells with mutant Ras proteins. As a possible
21
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reason for this difference, they suggested that cells with mutant Ras proteins are 
over expressed numerically, compared to cells with non-mutant Ras proteins. Thus 
cells with mutant Ras proteins need more biologically active compound to have 
the same results.58
A recent study evaluated the efficacy of Manumycin A 1 and BAL9611 
( a geranylgeranyl-transferase inhibitor) against human colon (SW620) cancer 
cells.59 The Ras superfamily of proteins are involved with cell proliferation in a 
number of different pathways which require post translational modifications to be 
biologically active. Two of the modifications to various Ras Proteins needed for 
post translational modifications include isoprenylations by famesyltransferase and 
geranylgeranyl-transferase. BAL9611 is a novel inhibitor of geranylgeranyl- 
transferase which has exhibited cytotoxicity towards colon cancers. The results of 
the study determined that when Manumycin A 1 and BAL9611 were combined, 
they have a synergistic apoptosis effect on the SW620 cancer cells. This 
synergistic effect enables the induction of cell apoptosis to occur with reduced 
amounts of both inhibitors rather than when the two compounds are employed 
separately. These promising results were exhibited both in vitro and in vivo, with 
the in vivo testing taking place in CD nu/nu female mice xenographed with 
SW620 tumours.59
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(1.6.8) Ovarian Cancer
Ovarian cancer affects thousands of women each year and is the most lethal 
gynaecological cancer.60'62 In an effort to determine why ovarian cancer is so 
resistant to treatment if the initial therapy is unsuccessful, two studies examined 
the total proteins extracted from cancer cells treated with Manumycin A 1.
In the two studies, it was discovered that soon after the treatment of 
resistant ovarian cancer cell lines (2774, OVCAR3, SFMAL) with Manumycin A 
1, heat shock proteins (HSP) 70 were up-regulated by the cancer cells.60,61 The 
IC50 using Manumycin A 1 against all ovarian cell lines and cell cultures tested 
had an efficacy of between 3.7 pM to 25 pM. The researchers were able to isolate 
and identify HSP 70 and an altered form of HSP 70 after treatment with 
Manumycin A 1. HSPs are a cellular defensive mechanism used to protect cells 
against damage that can cause necrosis or apoptosis. In the cells treated with 
Manumycin A 1, HSP 70 were the only HSPs to be up-regulated. HSP 70 is 
known to react to various forms of cell stress in order to protect the cell from late 
stage cell apoptosis. An inhibitor of HSP 70, 50 pM of quercetin, was evaluated in 
combination with Manumycin A 1. Quercetin significantly enhanced the efficacy 
of Manumycin A 1 towards ovarian cancer cells’ apoptosis. These results provide
the framework for a combinational “cocktail” for the treatment of ovarian
60-62cancers.
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(1.6.9) Mesothelioma Cells
Mesothelioma is a rare condition where a malignant tumour develops in the 
pleura or peritoneum and has been linked to exposure of asbestos fibre. Currently, 
there is no effective treatment for mesothelioma carcinoma. In the previously 
mentioned study on ovarian cancer, the researchers also examined the efficacy of 
Manumycin A 1 against mesothelioma cells (SFHAY, SFROB) cultured directly 
from patients and found the cancer cells to be significantly inhibited.61 Similar to 
ovarian cancer, the researcher discovered an up-regulation of HSP 70 after a 
treatment with Manumycin A 1. The authors of the study proposed that up- 
regulation of HSP 70 may be common to cancers resistant to standard 
chemotherapeutic treatments.61
(1.6.10) Anaplastic Thyroid Carcinoma
In North America there are about 15,000 new case of thyroid cancer per 
year, with three times more females being diagnosed with the disease than males.63 
Of the four types of thyroid cancer, 90 % of them are: Papillary, Follicular, mixed 
Papillary/Follicular or Hurthle cell. The prognosis for these common thyroid 
cancers is excellent with a better than 95 % cure rate. The last 10 % of thyroid 
cancers consist of Medullary and Anaplastic, with Anaplastic Thyroid Cancer 
being the rarest and most lethal.63 Patients with Anaplastic Thyroid Cancer (ATC) 
have a mean survival time of 3-7 months once diagnosis is made for this very 
aggressive solid tumour.64'68 The current therapeutic remedies include surgery,
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radiotherapy and chemotherapy. All have had little effect on patient survival rates 
and consequently, there is an egregious need for new therapeutic treatments.
Researchers at the University of Texas (Houston) tested Manumycin A 1 
alone and in combination with other drugs currently used to treat ATC .63 Present 
chemotherapy uses Doxorubicin and Cisplatin to treat ATC, while the use of 
Paclitaxel is still under clinical evaluation. These compounds were investigated for 
their efficacy with Manumycin A 1 against six human ATC cell lines: ARO,
C643, DRO, Hth-74, KAT-4, and KAT-18. The results of the study indicated 
Manumycin A 1 inhibited all six of the ATC cell lines in vitro in a dose dependent 
manner. Manumycin A 1 combined with Cisplatin or with Doxorubicin 
synergistically enhanced the cytotoxic effect for only five of the six ATC cell lines 
tested. However, when Paclitaxel was combined with Manumycin A 1, the two 
compounds exhibited a synergistic enhancement of cytotoxic effect more than 
their simple addition against all six ATC cell lines in vitro. To confirm the 
existence of a synergistic effect for manumycin A 1 and Paclitaxel against ATC 
cell lines, the authors of the study used the median-effect method of Chou and 
Talalay. The ATC cell lines evaluated using this method were ARO, DRO, C643, 
and Hth-74. Two additional cell lines were included in the Chou-Talalay methods’ 
evaluation, a pancreatic cancer cell line (PANC-1) and a breast cancer cell line 
(SK-Br3). The results of the evaluation indicated synergism for the combination of 
Manumycin A 1 and Paclitaxel against all six different cancer cell lines in vitro.
To determine if the combination of compounds would cause toxicity to normal
25
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
cells in vivo, studies using the nude mouse xenograft model were conducted with 
ARO and KAT-4 cells. No indications of increased toxicity to normal cells or to 
the health of the host animal were observed while using Manumycin A 1 and 
Paclitaxel together. In the KAT-4 cells, the combination of compounds exhibited a 
greater antitumour response than the individual compounds alone, but synergism 
was not observed in vivo. Further testing is needed to optimize the delivery of the 
two compounds to maximize therapeutic efficacy .64
In an effort to understand the enhanced apoptosis of Anaplastic Thyroid 
Cancer by Manumycin A 1 and Paclitaxel, two studies investigated the activation 
of the apoptotic pathway in ATC cells by the two compounds. ’ The first study 
used inhibitors of caspase-9, caspase-8  and caspase-3, to determine that
Manumycin A 1 and Paclitaxel initiated the apoptosis regulatory pathway at
(\1Cytochrome C or possibly even further upstream in the apoptosis pathway.
The second study determined that p21 Waf-1 (also called: Cip-1, Sdi-1, 
MDA-6  factor) expression was linked to ATC Kat-4 cells susceptibility towards 
Manumycin A 1 and Paclitaxel.68 By increasing the Waf-1 expression inside the 
ATC cells with a stable transfected plasmid that expressed p21 Waf-1 upon 
induction with Zn2+, the authors were able to show that Kat-4 cells were more 
sensitive to the two compounds as Waf-1 increased. A second set of experiments 
used HCT-116 p21 knock-out (-/-) cells and wild type human colon cancer cells. 
The knock-out (-/-) cells expressing no p21 Waf-1 were able to proliferate after 24 
hours of drug treatment with Manumycin A 1 and Paclitaxel. Whereas, the p21
26
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wild type (+/+) human colon cancer cells were inhibited by the combination of 
Manumycin A 1 and Paclitaxel. Thus, expression of p21 Waf-1 is pro-apoptosis 
when ATC cells are treated with Manumycin A 1 and Paclitaxel.68
In the first study, tumours treated with Manumycin A 1 in vivo were 
observed to be paler than the control tumours suggesting a decrease in 
vascularity.65 Angiogenesis, the process for new blood vessel formation, is a key 
factor in the continuous rapid growth of tumours. Without angiogenesis, tumours 
can only grow a few millimetres in size until they can develop an enhanced blood 
supply.66 Therefore, a sustained delivery of Manumycin A 1 should increase the 
efficacy against the continuous process of angiogenesis for tumours.65
Matrigel implants in mice are a common method used to determine the 
extent of angiogenesis in vivo. Treatment of the xenograft ATC mice with the 
human ATC cell lines: ARO, KAT-4, KAT-18 and Hth-74, with two Matrigel 
implants per mouse were evaluated. Manumycin A 1 injections significantly 
inhibited angiogenesis as demonstrated by measurement of the decreased 
haemoglobin content, the reduced amount of endothelial cells and the vascularity 
within the Matrigel implants.65 Vascular Endothelial Growth Factor (VEGF) is a 
mitogen (an agent that stimulates cell division) important to the process of 
angiogenesis. To discover if VEGF levels were being affected in ATC, the 
concentration of VEGF was evaluated for Manumycin A 1 and Paclitaxel 
individually and together in both tumour xenograft and tissue cultures of two ATC 
cell lines ARO and KAT-4. In vitro results showed Paclitaxel to exhibit a
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negligible effect towards VEGF, but Paclitaxel did seem to enhance Manumycin A 
1 efficacy towards VEGF. This same enhancement by Manumycin A 1 did not 
appear in the in vivo results for Paclitaxel. Manumycin A 1 did significantly 
inhibit VEGF in the two ATC cell lines in vitro and in vivo, agreeing with the 
results from previous studies using different famesyltransferase inhibitors.65
Pharmacokinetics, the dynamic behaviour of chemicals inside biological 
systems, suggests that the manner in which a compound is administered can affect 
its therapeutic efficacy as well as the degree of toxicity of the therapeutic 
treatment.65 As angiogenesis is a continuous process, slow release Manumycin A 1 
pellets and injections of Manumycin A 1 were evaluated individually and in 
combination with Paclitaxel against the ATC cell line KAT-4 in vivo. The results 
indicated that a sustained delivery of Manumycin A 1 had an improved efficacy at 
a lower combined dose than the injected Manumycin A 1 in vivo. Also, sustained 
delivery of Manumycin A 1, with or without Paclitaxel, exhibited no increase in 
its toxicity towards the mice with ATC. Thus, Manumycin A 1 and Paclitaxel 
inhibit angiogenesis in tumours and contribute to a significant antineoplastic (an 
anticancer drug) effect in vivo in addition to their direct cytotoxicity towards 
ATC .65
The potential of Manumycin A 1 for therapeutic treatments is exceptionally 
wide ranging in its possible future applications. Manumycin A 1 has shown 
promising results for antibiotic, antifungal, antiparasitic, anti-scarring, and 
antitumour properties. The antitumour properties of Manumycin A 1 show a
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potential against some of the most virulent cancers that presently do not have 
viable treatments. The potential research value of Manumycin A 1 by itself or as a 
sophisticated cocktail should not be understated.
(1.7) Synthesis of Manumycins and Their Analogues
Due to the difficulty of producing cost effective quantities of manumycins 
from their bacterial source, the need for a novel synthesis of the m-C7N unit is 
imperative to fully utilize the potential of all the 28 naturally occurring 
manumycins. Two main research groups having been working towards that 
endeavour. Richard J. K. Taylor leads a research group at the University of York 
and Peter Wipf directs another research group from the University of Pittsburgh. 
Both research groups have made initial progress towards discovering syntheses for 
some of the manumycins, but much work is still needed to fulfill the potential of 
manumycins.
(1.7.1) m-C7N Core Analogues
The epoxyquinone and epoxyquinol core is a common structural feature for 
many compounds isolated from natural products.69 In addition to manumycins, a 
number of smaller secondary metabolites displaying structural similarities without 
the “eastern” and “southern” polyunsaturated chains typical of manumycins have 
been isolated and characterized.69,70 Representative examples of these secondary 
metabolites are found in Figure 2 and include: MT 35214 3, LL-C10037a 4,
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Enaminomycin A 5, Enaminomycin B 6 , Enaminomycin C 7, MM14201 8 , 
Epoxydon 9 u , Epiepoxydon 10, Epoformin 11, Epiepoformin 12, Chaloxone 13,
7 0and Bromoxone 14. Initial research into the total synthesis of manumycins was 
built upon previous attempts to synthesize some of these smaller metabolites 
analogous to the m-C7N core. The secondary metabolites Bromoxone 14, MT 
35214 3, and LL-C10037a 4 were considered to be good analogues for examining 
potential stereoselective routes to various manumycins.61
(1.7.2) Synthesis of (+)-Bromoxone
(+)-Bromoxone 14 and its acetate derivative were first isolated from marine 
Acorn Worms (Phyllum hemichordata) found in deep sea caves off the coast of 
Maui.71 Discovered by Higa and co-workers in 1987, the structures were 
confirmed using X-ray analysis of the acetate derivative. The acetate derivative 
exhibited good antitumour activity against P388 cells (a type of leukemia) with an 
IC50 of 10 ng m L 1 in vitro.
The synthesis of racemic (+/-)-Bromoxone was first reported by Taylor and
77co-workers in 1994. An enantiomerically pure synthesis of (+)-Bromoxone 14 
through way of enzyme resolution by Johnson’s (1995)73, by Altenbach’s (2000) 
74, and by Kitahara’s (2003) 75 respective laboratories was also accomplished. 
Maycock et al. (2003) instead started with commercially available (-)-Quinic acid 
15, a compound from nature’s chiral pool, which had the correct cyclohexane
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OH
Br
14 (+) -Bromoxone
« 1 f tcarbon skeleton and a 1,4 oxygen functionality suitable for synthesis, (see 
Scheme 1) The (-)-Quinic acid 15 also already had the (4S)-hydroxyl functional 
group needed for the synthesis of (+)-Bromoxone 14. Maycock developed a 12 
steps synthesis from (-)-Quinic acid utilizing an aziridine functional group to 
protect the alkene and control the regiochemistry of the epoxidation of 16. The 
aziridine functional group was introduced stereoselectively to produce 16 as the 
major diastereomer in a 4:1 ratio. It is believed that this functional group has the 
strongest orienting effect in the subsequent stereoselective formation of epoxide
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17. Originally, the tert-butyldimethylsilyl (TBDMS) functional group was thought 
to control the stereochemistry of the epoxides’ formation due to steric hindrance. 
However, subsequent experimentation by the authors carried out on the minor 
deprotected product of 16 showed that it was the aziridine functional group that 
was directing the stereochemical outcome of the epoxidation. In this case, the 
minor diastereomer product was shown to have a syn (same side of the ring) 
configuration for the hydroxyl and epoxide functional groups after epoxidation. 
The minor isomer could therefore be used to pursue an asymmetric synthesis of 
LL-C10037a or manumycin analogues without the “lower” side chain.
(1.7.3) Synthesis of (+)-MT 35214
(+)-MT 35214 3 is the enantiomer to (-)-LL-C10037a 4 and its m-C7N 
core’s stereochemistry is analogous to only two manumycins, Nisamycin and
77Alisamycin. Taylor’s research group had reported the only asymmetric synthesis 
of (+)-MT 35214 3 , which was based upon the enantioselective chiral phase 
transfer epoxidation of an acetal protected quinone (see Scheme 2). Taylor’s group 
utilized Wynberg’s phase transfer epoxidation procedure using commercially 
available N-Benzylcinchonidinium chloride as the chiral catalyst to give 
compound (-)-19 a 71 % yield from 18 and with an enantiomeric excess (ee) of 89 
%. The total synthesis of 3 was completed in 7 steps from the commercially 
available starting material with an overall yield of 10 %. Taylor’s research group 
also tried to use a pseudoenantiomeric N-benzylcinchoninium chloride to produce
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the enantiomer (+)-19 but surprisingly this catalyst also gave (-)-19 in a lower 
optical yield of 10 % ee. The authors did not offer any explanation for this 
surprising result. Unfortunately, it was therefore concluded that this technique was 
unsuitable for the synthesis of (-)-LL-C10037a 4, the enantiomer of (+)-MT 35214 
3.
Scheme 2
NHBOCNHBOC
O
18 (-)-19
NHAc
O
NHAc
OH
20 3 (+)-M T 35214
Reaction C onditions77
a) t-BuOOH, NaH, N-benzylcinchoridinium chloride, (71%, 89 % ee) b) 1) CF3C 0 2H, (95%) 
2) AcCI, t-BuOLi (65%) c) 1) LiEt3BH (89%) 2) Montmorillonite K10 (90%)
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(1.7.4) Synthesis of (-)-LL-C10037a
The Streptomyces LL-C10037 secondary metabolite (-)-LL-C10037a 4 was 
first isolated in 1984 by Lee and co-workers from Lederle Laboratories.78 Its 
structure was later revised by Gould and co-workers based on the examination of a 
single crystal X-ray diffraction analysis and its stereochemistry was further 
confirmed by exciton circular dichroism studies of two derivatives of (-)-LL- 
C10037a 4 ,79 Gould and co-workers additionally proposed a biosynthetic pathway 
for (-)-LL-C10037a 4 based upon whole cell feeding with deuterated substrates 
and cell free studies.80,81 The biosynthetic route consists of six additional steps
o 1
from 3-hydroxyanthranilic acid derived from the Shikimic acid pathway. The 
antibiotic antitumour (-)-LL-C10037a 4 metabolite exhibited inhibitory activity in 
vitro towards a limited number of Gram-positive and Gram-negative bacteria with 
MIC values ranging from 64 -  128 mg mL'1. The compound (-)-LL-C 10037a 4 
also increased the life-span of mice with murine (relating to mice or rats) leukemia 
P388 by 29 % when intraperitoneal injections of an optimized dose were 
administered (25 pg g' 1) . 78
The synthesis of (-)-LL-C 10037a 4 has been reported by various research
7 0  87groups in both racemic and enantiomically pure forms. Wipf’s and then 
Taylor’s 83 research groups both have reported a racemic synthesis for the two 
enantiomers, (-i-)-MT 35214 3 and (-) LL-C10037a 4, that are quite similar.70 
Taylor and co-workers were able to reduce the number of synthetic steps to 7 and
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to increase the overall compound yield to 1 0  % from the same starting material, 
2,5-dimethoxyaniline 21, which was previously used by W ipf.83 (see Scheme 3) 
Taylor first protected the amine functional group in 21 then oxidized using 
phenyliodine diacetate (PIDA) in methanol before epoxidizing the resulting
Scheme 3
OCH,
NH,
OCH,
21
NHBOC
NH
(+/-) -22 
O
O
NHAc
V 0
NHAc
(+/-) -23
R eaction C on d ition s(
OH 
(+/-) -24/25
OH
3 (+)-MT 35214
4 (-)-LL-C10037a
a) 1) B0C20 , THF, rt 2) PIDA, MeOH, 0° C 3) H20 2 / K2C03, THF / H20 , rt, 5 days
b) BF3OEt2, CH2CI2, rt c) 1) AcCI, LiOBu', THF 2) NaBH4 3) TsOH, PPTs, aq. Acetone
intermediate with hydrogen peroxide and base to get compound (+/-)-22. To get to 
the key amine intermediate (+/-)-23, Taylor used boron trifluoride etherate to 
remove the t-butoxycarbonyl (BOC) protecting group. Compound (+/-)-23 was 
acetylated and the carbonyl was reduced to the corresponding alcohols with 
sodium borohydride. Hydrolysis of the dimethoxy acetal afforded a 1:3
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diastereomeric mixture of (+/-) 24/25 and their diastereomers (+)-MT 35214 3 and 
(-)-LL-C10037a 4. The separable 3:1 mixture of the diastereomers afforded a 10 
% yield for the racemic target enantiomer compounds (+)-3 and (-)-4.
The first enantioselective synthesis of (-)-LL-C 10037a 4 was reported by 
Wipf et al. in 1995.84 However, the use of multiple protecting groups, chiral 
auxiliary and two hypervalent iodine oxidations, resulted in a very low overall 
yield for this synthesis.
Later, an enantioselective synthesis of (-)-LL-C10037a 4 was reported by 
Johnson et al. 85 and Altenbach et al. 74, where both research groups used enzyme 
resolution of an intermediate to afford the stereoselectivity needed to isolate the 
enantiomer (-)-LL-C 10037a 4.
(1.7.5) Total Synthesis of Manumycins
The total synthesis of a number of racemic and enantiopure manumycins 
have been accomplished by Taylor et al. They published the first manumycin to be 
synthesized, (+/-)-Alisamycin in 1996, using the methodology to make the m-C7N 
unit derived from their earlier work with (+/-)-Bromoxone, and (+/-) LL- 
C10037a.86 Taylor and co-workers were soon to follow with the racemic 
synthesis of other manumycins: (+/-)-U-62162 87, (+/-)-Nisamycin88 and (+/-)- 
Colabomycin D .89 W ipf et al. also published a synthesis for (+/-)-Nisamycin in
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1999, based on their methodology developed for the m-C7N unit in their synthesis 
of (+/-) LL-C10037a.90
The first enantioselective synthesis of a manumycins was published by 
Taylor et al. in 1998.91’92 They reported the synthesis of (+)-Manumycin A 31, the 
enantiomer of the natural product (-)-Manumycin A 1. Using their methodology 
developed for the synthesis of (+)-MT 35214 3, (see Scheme 2) Taylor was able to 
stereoselectively make the protected quinone (-)-26 using Wynberg’s chiral phase 
transfer catalysis procedure, (see Scheme 4) The next step was the addition of the 
“eastern” polyunsaturated side-chain 26a (see box in Scheme 4) using an acid 
chloride derivative and then deprotection of the acetal to afford compound (-)-27 
in a moderate yield (6 8  %). To add the “southern” polyunsaturated side chain, 
Taylor utilized a two step procedure where first the vinyl-lithium reagent 28, was 
reacted with the quinone (-)-27 stereoselectively, but not regioselectively to afford 
compounds (+)-29a and (+)-29b. After isolating compound (+)-29a, the final step 
was a Stille coupling where (+)-29a is united to the bromo diene derivative 30 
using Negishi’s catalyst to afford the target molecule (+)-Manumycin 31. Based 
on this work, the previously published structure of the natural product (-)- 
Manumycin A 1 was revised to the new syn configuration for the epoxide and 
hydroxyl group found on the natural product.
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Scheme 4
H3 CO OCHg
o:
NH,2 a-d
O 9 H3  c h 3  c h 3
NH
O
(-) -26
0
(-) -27
BugSn
c h 3  c h 3  c h 3
(+ -29a
OH CH3  CH3  CH3  
NH
(+) -29b
O
Br 'NH
AO-vA s^OH 30
c h 3  c h 3  c h 3
c h 3  c h 3  c h 3
■v__/ C H 3
0  26a
(+) -31, Enantiomer of (-)-Manumycin A
Reaction C onditions91
a) t-BuOLi, THF, 26a
b) LiEt3BH, THF, -78 0° C
c) Montmorillonite K10, CH2CI2, rt
d) PDC, CH2CI2 , rt
(-)-Alisamycin was the next manumycin to have a total stereoselective 
synthesis published by Taylor et al. in 1998.77 Using the same methodology as 
they used to prepare (+)-Manumycin 31, Taylor was able to easily extend their
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previous research to make the natural product (-)-Alisamycin. The only change 
needed was to use an acid chloride derivative with the appropriate polyunsaturated 
“eastern” side chain fitting the structure of (-)-Alisamycin. Contrary to their 
previous synthesis of (+)-Manumycin where the enantiomer of the natural product 
was obtained, (-)-Alisamycin shares the same m-C7N core’s stereo-configuration 
as (+)-MT 35214 3, therefore, the synthesis of the natural product (-)-Alisamycin 
was possible rather than its enantiomer.77
In a continuation of their work on the total synthesis of manumycins,
Taylor et al. developed a methodology for converting type I manumycins into 
their corresponding type II manumycins. A number of the type II manumycin 
natural products discovered are just a reduced form of some type I manumycin 
natural products. The four type II manumycins, called TMC-1 A-D (see Appendix 
2 ), also exhibit cytotoxic activity to a range of tumour lines in vitro and 
structurally have a (3-hydroxy ketone configuration on their m-C7N core unit. By 
regioselectively reducing the corresponding analogous type I counterpart’s epoxy 
ketone m-C7N core unit, Taylor was able to synthesize (+)-TMC-l A from the 
reduction of (+)-Manumycin B with sodium phenylseleno(triethoxy)borate (Na 
[PhSeB(OEt)3] ). Taylor additionally reported the first synthesis of (+)- 
Manumycin B the enantiomer of the natural product (-)-Manumycin B, using their 
Wynberg chiral phase protocol for the m-C7N core unit.
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(1.8) Spirocompounds
Spirocompounds are a large class of inorganic and organic compounds that 
consist of multiple rings linked through one common atom. The nomenclature and 
the name spirane was first reported by A. Baeyer in 1900 for bicyclic compounds 
with one common atom to both rings.94 An interesting sub-category of this large 
class of compounds are the cyclic spiro-tyrosine metabolites isolated from a 
number of different natural sources. Some examples of this class of compounds 
includes: Aranorosin 32, Aranosinol A 33 and B 34, Aranochlor A 35 and B 36 
and Gymnastatins A 37, B 38, C 39, D 40, E 41 and 1 42, as shown in Figures 3 
and 4.
(1.8.1) Aranorosin Family of Compounds
Aranorosin 32 was first isolated from the fermentation broth of 
Gymnascella dankaliensis ( formerly named: Pseudoarachniotus roseus) and has 
been shown to exhibit positive biological activity towards a variety of fungi, 
bacteria and cancers on a micromolar scale in vitro?5 Aranorosin 32 has an 
unusual l-oxaspiro[4.5]decane ring system, (see Figure 3) its total synthesis has 
been reported by the two research groups of Wipf 96,97 and Taylor.98 Since its 
initial discovery in 1988, further Aranorosin like spiro-Tyrosine metabolites have 
been isolated and characterized.
41
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O OH
OH
33 Aranorosinol A
OH
32 Aranorosin
CH
CH
H CH
HO
OH OH OH
34 Aranorosinol B 35 Aranochlor A 36  Aranochlor B
O
H
R1 for com pounds 33-36
F igu re 3  Aranorosin Fam ily 
o f C om pounds98'101
The spiro-tyrosine secondary metabolites Aranorosinol A 33 and B 34 were 
isolated in 1992 from a strain of Pseudoarachniotus roseus." Both compounds 
contain the l-oxaspiro[4.5]decane ring system of Aranorosin 32 and exhibited in 
vitro inhibition of an assortment of bacteria and fungi in the pg mL' 1 range. A
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more recent examination of the biological properties of Aranorosinol A 33, 
showed the inhibition of POLO-like kinase 1 (Plkl) enzyme with a MIC of 
118pM.100 Plkl is a highly conserved kinase enzyme that has been revealed to be 
over-expressed in cancer cell lines and has an essential role in cell regulation. 
Therefore, Plkl is also a potential anti-cancer target for cancer research which is 
inhibited by a compound containing a l-oxaspiro[4.5]decane ring system.
Another study looking for solutions to the rapid emergence of antibiotic 
resistance in pathogenic bacteria found and isolated Aranorosinol B 34 
from a screening of 4000 microbes.101 Aranorosinol B 34 is a potent inhibitor 
against autophosphorylation of YycG, an essential histidine kinase in the stress- 
response pathway in bacteria. Comparative experiments against the established 
antibiotics cefazolin, amikacin, vancomycin, erythromycin and ofloxacin 
determined negligible inhibition of Bacillus subtilis YycG. Whereas, Aranorosinol 
B 34 inhibited YycG from both Bacillus subtilis and Staphylococcus aureus with 
an IC50 of 223 and 211 pM respectively. Thus Aranorosinol B 34 inhibits a 
biological pathways in bacteria current antibiotics do not utilize and therefore 
could be developed to be used against antibiotic resistance in pathogenic bacteria.
Two new additions to the Aranorosin family of compounds includes the 
isolation of secondary metabolites Aranochlor A 35 and B 36 in 1998 from 
Pseudoarachniotus roseus.102 Both metabolites contain the l-oxaspiro[4.5]decane 
ring system of the other aranorosins and also inhibit a variety of bacteria and fungi 
in vitro in the mg mL' 1 range. What is new to the aranorosin type carbon skeletons
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of both aranochlors is the addition of a chloroalkene in place of one of the 
epoxides. With the incorporation of a vinyl halide functional group into their 
structure, Aranochlor A 35 and B 36 posses a strong structural similarity to the 
spirocyclized gymnastatins, a family of compounds with potent cytotoxicity
. j  • 100,102towards various cancers.
(1.8.2) Gymnastatins Family of Compounds
In a search for new antitumour secondary metabolites from the marine 
environment, researchers in Japan isolated a number of biologically active 
compounds from the fungus Gymnascella dankaliensis.103 The fungus was 
discovered residing on the marine sponge Halichondria japonica which 
researchers were able to separate from the sponge and cultivate. After 4 weeks of 
growth in a salt water buffered medium, a variety of cytotoxic secondary 
metabolites were isolated from the fungus using multiple separation techniques to 
afford the following types of compounds: dankasterone , gymnasterones and 
gymnastatins. 103-106 Most of the metabolites examined exhibited moderate to high 
biological activity towards cultured p388 lymphocytic leukemia with an ED50 in 
the pg mL'1 to ng mL'1 range, (see Figure 4)
The Gymnastatins A-E 37-41 and Gymnastatin I 42 100 contain the 1- 
oxaspiro[4.5]decane ring system of the aranorosin family of compounds. 106 The 
total synthesis of Gymnastatin A 37 and Gymnastatin 142, along with various 
analogues have been accomplished and have been used to establish the absolute
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OH
37 Gymnastatin A
HO
OCH
H
HO"' ’OH
OCH
38 Gymnastatin B 39 Gymnastatin C
OH OH
OH
40 Gymnastatin D
OH
O
41 Gymnastatin E
OH
42 Gymnastatin I
CH3 c h 3
Rj is the polyunsaturated chain 
for all 6 Gymnastatins
Figure 4 Gymnastatin Family of
Spirocyclic Compounds100,106
stereochemistry of most of the compounds in this class.100 To date all the 
gymnastatins and aranorosins share the same 6 R configuration at the 4,6-dimethyl- 
dodecadiene-2E,4E-oic acid unit attached to the nitrogen. The cytotoxic activity 
of Gymnastatins A-E 37-41 against cultured p388 lymphocytic leukemia was ED50
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0.018 pg mL (37), 0.108 pg mL (38), 0.1061ug mL (39), 10.8 fig mL (40) and 10.8 
fig mL (41) respectively. 106
(1.9) Cyclohexadienone ketals and quinols
In synthetic organic chemistry many biologically active compounds 
targeted for synthesis share carbon skeleton fragments bearing similar functional 
groups that are often referred to as building blocks. Over time, some of these 
building blocks become highly developed intermediates repeatedly used by 
organic chemists for the unique regioselective and/or stereoselective controls that 
they afford. Cyclohexadienone ketals and quinols are examples of building blocks 
useful to chemists for their potential to develop enantioselective syntheses of 
natural products. 107 Between the two types of cyclohexa-2,5-dienones commonly 
used as building blocks for the synthesis of natural products, the masked para- 
benzoquinone ketals are more enantioselectively developed when compared to the 
para-quinols. (See Figure 5) Presently, there are a number of enantioselective 
syntheses using the masked para-benzoquinone ketals as building blocks to 
generate the m-C7N unit for some members of the Manumycin family of 
compounds. Additionally, masked para-benzoquinone ketals have also been used 
to generate enantioselective syntheses for the phenol Miroestrol, the ketals 
Preussomerin and Diepoxin, and the quinoid Jesterone. The generalized 
approaches developed to control the para-benzoquinone ketals’ enantioselectivity 
have included the applications of enantioselective reagents, enantioselective
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Figure 5 Enantioselective Syntheses using Masked Para-benzoquinone 
Ketals and Plausible Enantioselective Syntheses using Para-quinols.107
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catalysts, and chiral auxiliaries. On the other hand, the para-quinols have not been 
extensively used in the synthesis of many natural products in contrast to the 
masked para-benzoquinone ketals. The unrealized potential for enantioselective 
applications of para-quinols could increase dramatically if the lack of synthetic 
pathways to nonracemic para-quinols could be solved. Currently, only Aranorosin 
and a few gymnastatins have been enantioselectively synthesized using L- 
Tyrosine, an amino acid from the chiral pool and a major building block of those 
compounds. The development of a convenient methodology to produce 
enantioselective para-quinols could facilitate the synthesis of a number of
107important biologically active compounds as was illustrated in Figure 5.
(1.10) Development of Para-quinols Enantioselectivity
While there are many reports dealing with diastereoselective reactions 
involving para-quinols, a survey of the literature shows a lack of research
107concerning the enantioselective formation of para-quinols. The following
examples of enantioselective control involving para-quinols illustrate some of the 
limited research that has been developed thus far. Nishiyama et a l  discovered that 
the spirocompounds 43 and 44 when treated with the same Lewis Acid created 
different benzopyrans 45 and 46. (see Scheme 5) While this technique does not 
afford enantioselective formation of a para-quinols it does afford 
diastereoselective product resolution.108
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Scheme 5
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O
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An example of stereocontrol in the formation of para-quinols can be found 
in the work of Ponpipom et al..109 (See Scheme 6 ) They discovered by using 
different oxidants such as Lead (IV) acetate (L T A ) versus Thallium (III) nitrate 
(TTN), that different diastereoselective ratio of products could be obtained. 
Ponpipom’s synthesis for Kadsurenone 48 using TTN gave only the anti-isomer 
product (as shown in Scheme 6 ) due to the oxidant’s reaction mechanism and the 
steric effect of a methyl group located on the furan ring of the substrate. However, 
when the same starting material is treated with LTA, diastereoselective control is 
lost due to LTA’s reaction mechanism being different from TTN and is no longer 
influenced by the methyl group on the residue. This loss of diastereoselective
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control now afforded a product in a 1:1 ratio of syn and anti-isomers when using 
the oxidant LTA.
Scheme 6
h 3c o  o c h 3
LTA
H3CO o c h 3
MeOH
TI(N03)3
h2c ^
MeOHOH O
47 48 Kadsurenone
Furthermore, using the oxidant TTN does illustrate excellent diastereoselective 
formation of para-quinols, this technique is unfortunately very substrate specific 
and cannot be considered applicable to a large variety of substrates.
A more interesting synthetic strategy recently reported by Pettus in two 
articles involved the use of a tethered chiral chain to induce remote 
stereoselectivity for the formation of a pair of different para-quinols . 110’111 In the 
first report, Pettus used an (S)-lactic amide tethered chain attached to a phenolic 
derivative to diastereoselectively produce the para-quinol 50 in a 3:1 ratio .110 
(where the major diastereomer is shown in Scheme 7) After chromatographic 
separation of the para-quinols, and further modifications to the appropriate para-
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quinol, this work led to the enantioselective synthesis of (+)-bisorbicillinol in 
greater than 99% ee.
Scheme 7
OH O 0  0
H,C
CH
Major
Product
49 50
(+)-bissobicillinol
Reaction Conditions 110,111
a) PI FA, CHgClg/CHgNC^ (3:1) b) 1) conc. HCI, THF 
2) KOH, H20  3) H30 + work-up
Pettus then expanded on his original premise and found a new tethered 
amide chain that could induce a diastereoselectivity of 2 0 :1  for the 
oxidative cyclization of the phenolic derivatives (51-55) into para-quinols .111 A 
subsequent reduction and an elimination of the directing amide group afforded the 
chiral cyclohexenols (+)-(56 -60) with greater than 99% ee. (see Scheme 8 )
In an analogous synthetic strategy to Pettus, Plourde was able to show a 
diastereoselective spiroannulation from an assortment of racemic phenolic 
derivatives. 112 (see Scheme 9) Unlike when Pettus added a chiral auxiliary to the 
starting material that had to be removed later, Plourde incorporated the chiral
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Scheme 8
OH O
Where R = -alkyl, -allyl, -CN, -
(+H51-55)
HO
(+M56-60)
R
b,c
Reaction Conditions 111
a) 1) PIFA, CHgClg/CHgNOg (1 : 2.5) 2) H20  b) PtO, H2, MeOH 
c) KOTMS, Et20
centre directly onto the tethered para-alkyl residue of the phenolic derivatives. 
Plourde then utilized an intramolecular oxidation reaction with the tethered chiral 
chain to direct the diastereoselective formation for a number of racemic para- 
quinols. By starting with compound 61, a racemic mixture of R and S 
enantiomers, the oxidative spiroannulation created four stereoisomeric products 
giving two pairs of enantiomers, 62a/b and 63a/b. The ratios for the two groups of 
diastereomers 62 and 63, increased to a 4:1 ratio as the R group on the derivatives 
increased in size from a methyl group to a t-butyl group. Since 62 and 63 are
52
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diastereomers, their ratios could be determined by comparing the integration of 
^ -N M R  spectra of the crude products. The synthesis shows that the tethered 
chiral chain induces a facial selection in the oxidative spiroannulation forming 
these spiroether compounds.
In Scheme 9, the stereoconfiguration of the chain is not assigned to provide 
a simple representation of the four stereoisomers. Unfortunately, sometimes the 
Cahn-Ingold-Prelog rules cause a change in designation when changing R groups,
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without a corresponding change of inversion of the stereocenter. This occurs in 
Scheme 9, when representing the change from the methyl group to the two other 
functional groups, isopropyl and t-butyl. Therefore, the chiral tethered chain’s 
stereocenter is not represented and is only labelled to help represent the four 
different stereoisomers.
(1.11) Concluding Remarks
A review of the literature shows that there are two distinct problems with 
using the benzoquinone methodology for the synthesis of natural products. The 
first problem is a lack of stereoselective facial control for the synthesis of 
epoxyquinones and the second problem is a loss of regioselective control when 
attempting to connect the southern chain to the m-C7N unit of manumycins. This 
thesis is a study directed towards the diastereoselective formation of the 
manumycin m-C7N core using the quinol methodology. We believe that the pursuit 
of a simple solution to the regioselective control is to use a starting material that 
already has an alkyl chain attached to the ring. Similarly, the issue of facial 
stereoselectivity for epoxidation reactions is addressed by the use of a spirolactone 
intermediate. A spirolactone intermediate with a l-oxaspiro[4.5]decane 
configuration has previously exhibited an inherent stereoselective control for syn 
epoxidation reactions. The final problem of facial selectivity will be solved by 
using a chiral tethered chain to direct diastereoselective facial control. We believe 
that by using the quinol methodology this will address the problems associated
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with the benzoquinone methodology. Thus enabling us to produce the core m-C7N 
units stereoselectively for a majority of the manumycin natural products.
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Chapter 2 
Results and Discussion
(2.1) A Novel Diastereoselective Methodology for Para-quinols
An interest in developing synthetic strategies for controlling the facial 
selectivity for the asymmetric formation of spirolactones and spiroethers, led us to 
investigate and develop a synthetic method using a chiral tethered chain. The 
significance of these types of para-quinols is their potential to be used as building 
blocks for the asymmetric synthesis of many natural products. In the course of 
examining previously published methods for the formation of spirocompounds, it 
was observed that the aranorosin and gymnastatin families of compounds shared 
many structural features with the central core ra-C7N unit of the compounds from 
the manumycin family. This similarity was especially apparent if the 
spiroether/lactone moiety was imagined to be opened. From this observation, a 
plan was developed to incorporate our ongoing interest in asymmetric 
spiroannulations into an approach to create a stereoselective analogue for the core 
m-C7N unit of the manumycin family of compounds. As was previously 
mentioned in Chapter 1, the manumycin compounds exhibit a vast range of 
potential applications in many areas of research and medicine yet, currently only 
one para-quinol stereoisomer can be made proficiently.
Therefore, the ultimate goal of our research group is to synthesize the 
simple idealized target molecule 64 (see Figure 6 ) that represents the
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stereoselective core m-C7N unit for a majority of the manumycins. However, first 
we needed to determine the validity of using a tethered chiral chain to induce 
diastereoselective control for the formation of spirolactones. The simple target 
molecule 64 was therefore devised to include the specific criteria relating to
the proposed methodology of an asymmetric spiroannulation from a (L)-Tyrosine 
derivative. By utilizing a (L)-Tyrosine derivative from the chiral pool of amino 
acids, we afford ourselves the ability to quickly test whether employing a tethered 
chiral chain would induce the desired diastereoselective control for the formation 
of the spirolactone residues. An additional benefit to using an (L)-Tyrosine 
derivative is that the (D)-Tyrosine isomer is available commercially and therefore 
affords the opportunity to produce both para-quinol enantiomer based solely on 
choice of starting material.
O
OH
64
Figure 6 T he Target M olecule 
m-C7N unit analogue
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(2.2) Test Reactions for the Spiroannulation of (L)-Tyrosine
The first step in the process for the development of the asymmetric 
synthesis was to confirm that using a new substituent, Toluenesulfonyl (Ts), on 
the amino functional group of (L)-Tyrosine would not negatively affect the 
oxidative spiroannulation reaction.95 Typically, spiroannulation of Tyrosine has 
been done with other substituents (N-Ac, N-Cbz, N-BOC, N-phthalamido) and to 
our knowledge this is the first recorded synthesis using the N-Ts substituent. 
Therefore, a number of test reactions using (L)-Tyrosine with a Ts residue 
attached to the amino functional group were carried out. Additionally, these test 
reactions allowed us to further optimize the reaction condition for the 
spiroannulation with the new type of starting materials.
Initial attempts for selective tosylation of only the amino functional group 
on the Tyrosine amino acid were problematic. The innate nature of the Tyrosine 
compound is for tosylation to occur at both the amino and the phenolic hydroxyl 
functional groups concurrently. There are varying strategies in the literature 
involving multi-step synthesis with up to two different types of protecting groups 
for adding a substituent to the Tyrosine compound’s amino functional group. 113,114 
However in 2001 Ciufolini et al., reported a three pot synthesis for the formation 
of (N-Ts)-Tyrosine 65 115~117 but, in an effort to utilize an efficient total synthesis a 
novel two pot synthesis was developed to produce (N-Ts)-Tyrosine 65 (See 
Scheme 10). Instead of combating Tyrosine’s propensity for quantitative di- 
tosylation with tosyl chloride, 118 we alternatively cleaved the tosylate back into a
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hydroxyl group forgoing the need for any additional reaction steps with protecting 
groups altogether.119 The different reaction conditions needed to cleave the tosyl
190group from the amino moiety on the (L)-Tyrosine compound led to 
simplification of the synthetic procedure for the formation of (N-Ts)-Tyrosine 65.
Scheme 10
OH OH O
>
Ts-HN
Ts-HNOH
L-Tyrosine 65 66
Reaction Conditions
a) 1) TsCI Et20 ,  1 M NaOH 2) KOH EtOH, 8 0 -8 5  °C
b) PIDA, PIFA or LTA in A ceto n e at 0  °C - rt
The di-tosylation of L-Tyrosine proceeded smoothly with the formation of a white 
suspension. The work up in the literature cited was temperamental118 so it was 
modified to an acidification with hydrochloric acid (pH 1-2), followed by the 
extraction of the aqueous mixture with ethyl acetate to afford the crude 
intermediate di-tosyl-tyrosine. The crude product was then selectively detosylated 
with potassium hydroxide in ethanol overnight at 85-90 0 C. Compound 65 was 
obtained as a white solid in a 92 % yield from the starting material (L)-Tyrosine 
after silica gel chromatography.
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After the synthesis of compound 65, the oxidative spiroannulation reactions 
were evaluated on small scale using various reaction conditions with three 
different oxidants (Phenyliodine (III) diacetate (PIDA), Phenyliodine (III) bis 
(trifluoroacetate) (PIFA), Lead (IV) acetate (L T A )121"124) and were found to 
proceed to the (N-Ts)-Tyrosine spirolactone 66 with no unexpected complications. 
The PIFA in acetone reaction was repeated on a larger scale and purified for 
analytical information and afforded 66 a 36 % yield. It should be noted, that since 
these were test reactions to ascertain the effect of the Tosyl group on the 
spiroannulation of the (L)-Tyrosine derivative, compound 66 was not fully 
characterized and assignments of the structures were based solely on the *H and 
13C NMR spectra of the purified product. As well, the spirolactone 66 does not 
contain a new chiral centre at the spirocarbon, so we proceeded with the next 
series of reactions using the 3-Nitro-Tyrosine as starting material.
(2.3) Spiroannulation of (L)-3-Nitro-Tyrosine Derivative
To evaluate the premise that a tethered chiral chain could direct 
diastereoselectivity we proceeded with spiroannulation of the 3-Nitro-Tyrosine 
tosyl protected derivative. Formation of the (N-Ts)-3-Nitro-Tyrosine derivative 67 
using the test reactions conditions from Scheme 10 occurred much more slowly 
and with a lower yield (25-54 %). However, it was found that by substituting 
tetrahydrofuran (THF) for diethyl ether the reaction rate was increased along with 
the total isolated yield for compound 67 to 8 6 % (See Scheme 11). The
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spiroannulation of compound 67, unlike the test reactions for the spiroannulation 
of compound 65 did not proceed as expected. While thin layer chromatography 
(tic) seemed to suggest the reaction was proceeding
Scheme 11
OH OH O
NO NONO
Ts-HN
Ts-HNOH OH
L-3-Nitro-Tyrosine 67 68
Reaction Conditions
a) 1) TsCI THF, 1M NaOH 2) 1M KOH EtOH, 80-85 °C
b) PI DA, PIFA or LTA in Acetone at 0 °C - rt
correctly and a ^ -N M R  spectrum of the crude product exhibited trace amounts of 
the expected product, purification using silica gel chromatography did not allow us 
to isolate the spirolactone 6 8 . After many futile attempts using a myriad of 
reaction conditions and purification techniques, we re-examined the spirolactone 
6 6  product for possible problems. It was decided that the nitro functional group 
being such a strong electron withdrawing group (EWG) at the 3-postion on 
compound 67, might be interfering with the oxidative spiroannulation reaction.125' 
127 To determine a possible solution to the problem, new test reactions were
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devised to confirm that an electron donating group (EDG) would rectify the 
problem.
(2.4) Spiroannulation With An Electron Donating Group Derivative
The new test reactions consisted of a simplified non-Tyrosine version of 
(N-Ts)-3-Nitro-Tyrosine 67 but bearing an EDG instead of an EWG. To make the 
starting material, a Knoevenagel condensation with the Doebner modification was 
used to extend the aldehyde on 4-Hydroxy-3-nitrobenzaldehyde to a propenoic 
acid moiety as shown in Scheme 12, giving 69 in 93 % yield. Compound 69 could
178 170be used without purification. ’ Hydrogenation transformed the nitro functional 
group to an amine while also reducing the alkene on the para-chain to a propanoic 
acid residue. 130 Due to compound 70 decomposing quickly with handling, the 
amine was directly converted into two different types of amides with either acetyl 
chloride or benzoyl chloride, making the new EDG’s at the 3-position of the 
benzene ring for compounds 71 and 72 with yields of 48 % and 83 % from 69.131
With compounds 71 and 72 in hand, we proceeded with testing whether the 
oxidative spiroannulation would proceed as expected with an EDG. The small 
scale oxidative spiroannulation of the derivatives 71 and 72, using the reaction 
conditions used in our first test reactions, (1 to 3 equivalents oxidant, in acetone at 
0 °C) proceeded with good yields for both compounds using all three oxidants as 
determined by *H-NMR spectra of the crude products (see Scheme 13). Thus, 
confirming our suspicions that the strong electron withdrawing nature of the nitro 
functional group was the cause of our previous difficulties with the
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Schem e 12
4-Hydroxy-3-nitrobenzaldehyde
O ' OH
H
OH OH H
NH
OH OH
70 71 R= CH
Y
o
7 2  R= Ph
Reaction Conditions
a) 1)M alonic acid, pyridine, piperidine, 6 0 -6 5  °C, 2) H30 + b) H2, Pd/C, THF
c) AcCI or BzCI , THF, rt
spiroannulation of (L)-3-Nitro-Tyrosine derivative. The reactions with 71 and 72 
using PIFA in acetone were repeated on a larger scale and purified giving 96 % 
and 86 % yields for (+/-)-73 and (+/-)-74 respectively.
Scheme 13
OH H
O '  OH
O Hi
N
>
O H
N
Y '
O
R
71 R= CH,
72 R= Ph
(+/-)-73 R= CH3 
(+/-)-74 R = Ph
(+/-)-75 R= CH3 
(+/-)-76 R=Ph
Reaction Conditions
a) PIDA, PIFA, or LTA, Acetone, 0 °C - rt b) H20 2 /NaHC03 [3:1] THF/ H20
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The amide spirolactones (+/-)-73 and (+/-)-74 both contain a racemic 
mixture of enantiomers and share a spirolactone carbon skeleton with the 
Aranorosin (see Figure 3) and Gymnastatin (see Figure 4) families of compounds. 
Furthermore, assuming that the electron poor alkene (or least substituted alkene 
functional group) of compound 73 and 74 can be selectively epoxidized, the novel 
compounds 75 and 76 would represent racemic analogues of the m-C7N unit’s 
carbon skeleton found in the manumycin family (see Figure 2) and would be one 
reaction away from being a m-CjN  unit.
To show that it was possible to control the regio and stereoselective 
epoxidation of these spirocompounds 73 and 74, we examined the hydrogen 
peroxide reaction on the racemic mixture of compound 74. The un-optimized 
treatment of 74 with hydrogen peroxide and sodium bicarbonate in THF and 
water, led to the epoxidation of the electron poor alkene on 74 giving compound
1 '3 ' )  1 *17
(+/-)-76 in a low isolated yield of 7 %. ' The regioselective aspect of the
epoxidation on the electron poor alkene was confirmed by a Distortionless 
Enhancement by Polarization Transfer -135 (DEPT-135) NMR spectrum. The 
two carbons of the epoxide ring with one attached hydrogen each (a methine 
group, (CH)), showed two CH signals in the DEPT-135 NMR spectrum at 51.5 
ppm (C-6) and 55.4 ppm (C-7). These signals were in the range one would expect 
to see epoxide CH signals (40-80 ppm from the internal standard of 
tetramethylsilane (TMS)) (See Figure 7 and page 115 in Appendix 1). Conversely,
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if the epoxide had formed on the electron rich alkene (or more substituted alkene) 
there would have been only one CH signal, as C-9 is a quaternary carbon and does 
not have hydrogen attached. The stereoselective aspect of the syn epoxidation, 
between the oxirane and the lactone’s oxygen, also has literature precedent for 
nucleophilic reactions occurring with high 7t-facial selectivity towards the alkene 
on the cyclohexadienone ring and to proceed with the syn configuration with 
respect to the lactone oxygen.95,138 141 Hence we assume that the epoxidation will 
produce (+/-)-76 with the relative stereochemistry as shown in Figure 7, although 
we were unable to prove this assignment as of yet.
(+/-)-76
Figure 7 Compound (+/-)-76 with the proposed relative 
stereochemistry and labeled carbons for the DEPT-135.
Now that we confirmed the feasibility of our synthetic method to synthesize 
the racemic carbon skeleton analogues of the m-C7N unit of the Manumycin 
family of compounds, we returned our attention back to using a chiral tethered
O
II H
r  ?
3 2
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chain in order to ascertain the possibility of controlling the diastereoselective 
formation of the spirolactones.
(2.5) Diastereoselective Formation of Spirolactones
The diastereoselective formation of the spirolactones using a tethered chiral 
chain was accomplished using the EDG Tyrosine derivates 78 to make the 
spirolactone compounds (+)-79 and 80 (see Scheme 14). By taking the information 
learned from the EDG test reactions study we were able to successfully complete 
the spiroannulation of compounds (+)-79 and 80. The previously prepared 
compound 67 (Scheme 11) was reduced to the amine 77 using hydrogen with a 10 
% palladium/carbon catalyst. Due to instability problems with purifying the crude 
product, compound 77 was reacted directly with AcCl to form the amide 78 in a 
59 % yield for the two reactions. With an EDG at the 3-position on the benzene 
ring of the Tyrosine derivative, the small scale oxidative spiroannulation reactions 
with the three oxidants proceeded as expected using the methodology from the 
first test reactions study (1 to 3 equivalents oxidant, in acetone at 0 °C). It is clear 
from 'H-NMR spectra of the crude products that we now have a mixture of 
diastereomers. The use of an EDG on the 3-position of the aromatic ring for 
compound 78 solved the previous problem of the spiroannulation reactions and 
allowed the formation of the diastereomers with selectivity. Using the integration
66
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of the !H-NMR spectrum signals for H i , H2, and H3 of the crude products 79 and 
80 (see Scheme 14) we were able to estimate the ratio of diastereomers. The 1H- 
NMR spectrum peaks’ integration ratios for Hi (6.25 ppm major - 6.30 ppm minor 
diastereomer), H2 (7.06 ppm major -  6.92 ppm minor diastereomer), and H3 (7.52 
ppm major -  7.66 ppm minor diastereomer) were compared and gave us a major to 
minor ratio of [3:1] for compound (+)-79 and 80 respectively (see pages 125-128 
in the Appendix 1 for expansions of ^ -N M R  spectra).
Scheme 14
Ts-HN
Ts-HN
Ts-HN
O OHO OH
O H
O OH Ts-HN O
78 (+)-79
Reaction Conditions
a) H2 , 10% Pd/C, in THF b) AcCI, THF, rt
c) PIDA, PIFA, or LTA, Acetone, rt
CHH
H
NH-Ts
80
However, after separating the two diastereomers (+)-79 and 80 by silica gel 
chromatography we obtained a higher ratio of major and minor diastereomers 
(using their isolated masses, 18 mg: 1 mg). A larger scale reaction using PIFA as
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the oxidant, gave a silica gel chromatography separation of 38 mg for the major 
diastereomer, 54 mg for a mixture of major and minor diastereomers, and only 
8mg of the minor diastereomer (total yield of 85 %). While the mass-to-mass ratio 
does not agree with the !H-NMR integration ratio, there is precedent in the 
literature for spirolactones to react with silica gel and this could be the cause for
119 197the discrepancy. ’ Another possibility is one of the diastereomers may 
decompose at a different rate with the silica gel than the other diastereomer.
Scheme 15 shows the proposed reaction mechanism for the PIFA oxidant 
reacting with compound 78 in order to prepare the two diastereomers as shown 
above. PIFA reacts with the phenolic hydroxyl creating a hypervalent iodine 
complex. The conjugate base deprotonated the carboxylic acid which initiated the 
spiral annulation of the hypervalent iodine complex creating the two 
diastereomers. The structure 81 in Scheme 15 represents the anticipated 
diastereomeric transition state where the labels S, M and L represent the functional 
groups and their size: S for hydrogen, M for carboxylic acid and L for toluene 
sulfonylamide. The proximity of the tethered chiral chain to the aromatic ring 
limits the free rotation of the chiral center and the chiral center’s interaction with 
the hydrogen protons Ha and Hb on the aromatic ring causes the resulting 3 to 1 
diastereoselectivity. We suspect that the transition state of 81a leads to the major 
isomer (+)-79. In this configuration the large sulfonylamide group orients itself on 
the side of the proton Ha where steric factors are less important than the transition
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state 81b. In the transition state 81b a model study shows a larger steric hindrance 
between the sulfonylamide, the proton Hb, and the acetamide functional groups, 
thus leading to the minor diastereomer 80.
Scheme 15
CF.
Ph Ph.CH.NH
CHNH
CF.
Ha'
PIFA OH
Ts-HN NH-Ts H
CH.
Ha' Hb
CH.NH
81a
CH
Ha' .Hb Ts-HN
81b (+) - 79 or 80
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Chapter 3 
Conclusions
(3.1) Racemic Analogues
The syntheses from Scheme 12 and Scheme 13 in Chapter 2 illustrate a 
convenient method to incorporate the “Eastern side chains” from any of the 28 
Manumycins into the starting material for oxidative spiroannulations. The new 
synthetic route allows us to create a racemic core m-C7N unit analogue for each 
manumycin natural product. This novel methodology allows for starting from the 
commercially available 4-Hydroxy-3-nitrobenzaldehyde and five steps later 
assembling the carbon skeleton of the m-C7N core unit. With this methodology we 
can incorporate any of the 28 manumycin “Eastern side chains” to make new 
analogues (as shown in compound 83 and compound (+/-) -76  in Figure 8 and 
Scheme 13, respectively). These new analogues will allow for further biological 
research related to their possible medicinal properties. Please note, as was 
previously mentioned in the introduction in sections 1.5.1, 1.5.2, 1.5.3 and 1.5.6 
racemic manumycin benzoquinones also exhibited similar biological activities as 
their natural product counterparts. Consequently the “Southern side chain” is 
believed to be non-essential for certain Manumycin biological activities. As a 
result, this method allows for the synthesis of new compounds not of the 
benzoquinone 80 morphologies but of the para-quinol 81 configuration. Thus
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expanding on previous research and creating new compounds that could exhibit 
similar or greater biological activity based on their structural similarity to the m- 
C7N core units (Figure 2), to the aranorosins (Figure 3), to the gymnastatins 
(Figure 4), and to the manumycin families of compounds (Appendix 2). An 
additional advantage to creating analogues with this procedure is the high regio 
and modest stereoselective control afforded to the formation of the oxirane versus 
the racemic formation of the benzoquinone oxiranes. The para-quinol analogue 
81, having the syn configuration between the oxirane and the spirolactone oxygen, 
could possibly improve the biological activity of these compounds compared to 
the racemic benzoquinone analogue 80. Subsequent biological testing will now 
allow for the determination of the importance for this structural feature for 
manumycin analogues.
0 H O H
O
R= "Eastern Side Chai..~ 
of Manumycins
NV
o
R
'O
81
(+ /- ) -P a r a -Q u in o ls
A n a lo g u e s
R
80
(+ /- ) -B e n z o q u in o n e
A n a lo g u e s
Figure 8 Comparing Benzoquinones 
to Para-Quinols
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(3.2) Diastereoselective Analogues
The use of a tethered chiral chain on the (L)-Tyrosine derivatives in 
Scheme 14 is a viable method for inducing diastereoselective formation of para- 
quinol intermediates. The oxidative reaction produced a major and a minor 
diastereomeric spirolactone ratio ((+)-79 and 80, 3:1 respectively), thus 
confirming a facial discrimination caused by the tethered chiral chain. Similar to 
the research by Pettus 110,111 and Plourde 112, the use of a tethered chiral chain has 
exhibited a preference for the formation of a specific diastereomer. While the 
previous racemic formation of spirolactones allowed us to create racemic m-C7N 
core unit analogues, the use of a tethered chiral chain now allows for the formation 
of two diastereomer m-C7N core unit analogues that are amenable to flash column 
chromatography. The ability to separate these two diastereomers potentially allows 
for future synthetic modification for the stereospecific formation of a m-C7N 
Manumycin core unit analogue. Additionally, the commercially available D- 
Tyrosine, having the opposite configuration on its tethered chiral chain, could also 
be used in future work as the starting material to produce the other enantiomer as 
the major product. Therefore, the production of either enantiomer form of the 
major isomer can now be controlled by the selection of the appropriate (D)- or (L)- 
Tyrosine starting material. Another benefit to using a spirolactone derivate is that 
acid hydrolysis of the minor product reverts back to the original starting material 
before oxidation. This would allow for an increase in the total conversion of the
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starting material to the desired stereoisomer through the recycling of the minor 
product.
(3.3) Future Work
Future work associated with our findings would address the limitations 
currently existing in the thesis. In the synthesis of the racemic analogues, in 
Schemes 12 and 13, all but one of the reactions occurs with good yields. The 
epoxidation reaction has a low yield of 7 % and additional work needs to be done 
to increase the yield for this reaction. To solve this problem, further research could 
explore new reaction conditions with the current reagents to see if changing the 
reaction variables can increase the yield. Additional research could also focus on 
using new reagents and conditions for the epoxidation reaction in an effort to 
increase the yield while retaining the regio and stereochemistry of the current 
products. Supplemental analytical experimentation to confirm the syn 
configuration of the products using either an NOE experiment and/or x-ray 
crystallography should also be completed. The current core m-C7N unit analogue 
products shown in Schemes 12 and 13, are only one reaction away from being 
actual m-C7N core units. Therefore further research to achieve the cleavage of the 
lactone rings of the racemic products should also be continued and investigated.
The use of a tethered chiral chain on the (L)-Tyrosine derivatives in 
Scheme 14 allows for further experimentation regarding the diastereoselective
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formation of compounds like (+)-79 and 80. This thesis was but a first attempt to 
show that using a chiral tethered chain could induce facial diastereoselectivity for 
the oxidative spiroannulation of spirolactone derivatives. Now that there is 
evidence to support our original assertions this opens up a large area to do further 
research for the many para-quinols compounds previously mentioned in Section 
1.9 of the thesis. Initial research should examine the reaction mechanisms and the 
basis of diastereoselectivity caused by all three oxidants. The current low 
diastereoselectivity limits how effective the methodology is and further 
examination of the reaction mechanism should increase the likelihood of 
increasing the diastereoselectivity. The use of a chiral catalyst or reagent should 
also be considered as a means to improve the facial diastereoselective ratio. 
Concurrent research should also examine the implementation of new types of 
tethered chiral chains as a means to increase diastereoselectivity. By changing the 
sizes of the functional groups surrounding the chiral center, steric hindrance may 
also be enhanced with a possible corresponding increase in diastereomeric ratio. 
Additional research into oxidative spiroannulation would also entail using TTN to 
see if the different mechanism of the oxidant would amplify diastereoselectivity as 
Ponpipom et al.109 had good success improving stereoselectivity using this 
reagent. Further investigation of the compounds (+)-79 and 80 would entail a 
number of reactions consisting of a stereoselective epoxidation, a cleavage of the 
lactone ring and deamination of the sulfonylamide on the tethered chiral chain to 
produce manumycin analogues. In addition, further analytical experimentation to
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confirm the syn configuration between the oxirane and the lactone oxygen using 
either an NOE experiment and/or x-ray crystallography.
(3.4) Final Remarks
The confirmation of our ability to induce diastereoselective facial control 
using a tethered chiral chain represents a small positive step towards our ultimate 
goal of producing compound 64 regio and stereoselectively. Additionally, this 
preliminary study demonstrates the first attempt at controlling facial selection for 
the formation of spirolactones and allows for the potential development of new 
synthetic pathways using spirolactones as a building block in the synthesis of 
natural products. These types of compounds, as has been previously mentioned, 
have exhibited numerous different biological activities and extensive biological 
testing is therefore recommended.
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Chapter 4 
Experimental
Infrared (IR) spectra were recorded on a FT-IR Perkins System 2000 
spectrophotometer. Mass spectra were recorded with a Hewlett Packard (Agilent) 
5989 B Mass spectrometer (MS) with a 5890 Series II Gas Chromatograph (GC). 
Optical rotations were obtained using a Rudolf Research Autopol III instrument. 
Flash column chromatographies were carried out using Silicycle silica gel (230- 
400 mesh, 60 A). Analytical thin layer chromatography (tic) was carried out on 
silica gel coated aluminum plates from Silicycle (60 A, indicator F-254, thickness 
250 pm). Visualization of tlc-plates was accomplished with UV light (Short-wave 
UV, 254 nm) and/or by staining with Vanillin (27g of vanillin, 50 mL water, 380 
mL ethanol, 20 mL conc. sulfuric acid). LH (300.13 MHz) and 13C (75.47 MHz) 
NMR spectra were recorded on a Bruker AMX 2-300 spectrometer using 
tetramethylsilane (TMS) as an internal calibration standard when using deuterated 
chloroform. When using other deuterated solvents, spectra were calibrated using 
chemical shifts of residue protons of the deuterated solvent used. Chemical shifts 
(8 ) are quoted in parts per million (ppm) and H spin coupling (J) values are in Hz. 
Two-dimensional NMR spectra were used to elicit further chemical shift 
information and confirm compound structures.
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General Methodology of Small Scale Oxidations:
PIDA: To the starting material (20-30 mg, leq.) dissolved in acetone (lOmL, 0 °C) 
was added PIDA in one portion (2.1 eq.) and the solution was stirred until 
completion. Reaction progress was followed by tic (40-60 min). The solution was 
diluted with ethyl acetate (20-25 mL) and washed with cold water (10 mL). The 
organic fraction was dried (M gS04) and the solvent was evaporated. The residue 
was left under vacuum overnight to evaporate off phenyl iodine.
PIFA: To the starting material (20-30 mg, leq.) dissolved in acetone (lOmL, 0 °C) 
was added PIFA in one portion (1.01 eq.) and the solution was stirred until 
completion. Reaction progress was followed by tic (15-30 min.). The solution was 
diluted with ethyl acetate (20-25 mL) and washed with cold water (10 mL). The 
organic fraction was dried (M gS04) and the solvent was evaporated. The residue 
was left under vacuum overnight to evaporate off phenyl iodine.
LTA: To the starting material (20-30 mg, leq.) dissolved in acetone (lOmL, 0 °C) 
was added LTA in one portion (3 eq.) and the solution was stirred until 
completion. Reaction progress was followed by tic (15-30 min.). Ethylene glycol 
(4-5 drops) was added to the solution and it was left to stir overnight (14-16 hrs). 
The reaction mixture was filtered through Celite ® while rinsing with acetone (10- 
20 mL) and the solvent was evaporated. The residue was left under vacuum 
overnight to evaporate off ethylene glycol.
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(2S)-2-{[(4-methlphenyl) sulfonyl] aminoj-3-(4-{[(4-methylphenyl) sulfonyl] oxy} 
phenyl) propanoic acid Intermediate to 65: To a solution of L-Tyrosine (374 mg, 
2.06 mmol, 1 eq.) in 1M NaOH (50 mL) was added a solution of TsCl (2.843 g, 
14.91 mmol, 7 eq.) in diethyl ether (100 mL) in three portions (5 min. apart) at 
room temperature and the resulting mixture was stirred vigorously for 4-5 hrs. 
(confirmed by tic: [2:8] MeOH/CHCl3). The resulting white suspension was 
acidified with 10% HC1 (pH 1) and extracted with ethyl acetate (3 x 100 mL). The 
organic fractions were combined, washed with saturated NaCl (150 mL) and dried 
(M gS04). The solvent was then evaporated to afford a white solid (crude 938 mg, 
93 % yield). The product was used in the following reaction without further 
purification. Molecular Formula - C23H23NO7S2. Formula Weight - 489.56 g mole' 
\  Rf (EtOAc) = .65. *H-NMR (CDC13) 8 : 2.40 (s, 3H, H-7'), 2.44 (s, 3H, H-7"), 
2.90 (m, 1H, H-3a), 3.08 (m, 1H, H-3b), 4.12 (m, 1H, H-2), 5.28 (d, 1H, J = 8 .8 , 
N-H), 6.81 (d, 2H, J = 8.3, H-5, H-9), 6.99 (d, 2H, J = 8.3, H-6 , H-8 ) 7.21 (d, 2H, J 
= 8.1, H-2', H-6 '), 7.31 (d, 2H, J = 8.1, H-2", H-6 "), 7.55 (d, 2H, J = 8.1, H-3', H- 
5’), 7.67 (d, J = 8.1, H-3", H-5") 9.28 (broad s, 1H, C 0 2H). 13C-NMR (CDC13) 8 : 
21.74 (C- 7"), 21.94 (C- 7'), 38.24 (C- 3), 56.49 (C- 2), 122.69 (C- 5, C- 9), 127.20 
(C- 3', C- 5') 128.66 (C- 3", C- 5"), 129.96 (C- 2', C- 6 '), 130.04 (C- 2", C- 6 ") 
130.87 (C- 6 , C-8 ), 132.31 (C- 4), 134.17 (C- 4'), 136.31 (C- 4"), 144.32 (C- 1'), 
145.75 (C- 1"), 148.99 (C- 7), 175.30 (C- 1).
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(2S)-3-(4-hydroxylphenyl)-2-{[(4-methylphenyl) sulfonyl] amino} propanoic acid 
(65): To a solution of the intermediate of 65 (750 mg, 1.534 mmol, 1 eq.) in 
ethanol (100 mL) was added a solution of 1M KOH (50 mL) and the white 
suspension was heated (77-82 0 C) while stirring for 6-7 hrs (confirmed by tic:
[1:1] EtOAc/Hexane after mini work up, 10% HC1 and extracting with EtOAc.). 
The resulting mixture was left to cool, then acidified with 10% HC1 (pH~l) and 
extracted with ethyl acetate (150 mL, 50 mL). The organic fractions were 
combined, washed with saturated NaCl (150 mL) and dried (M gS04). The solvent 
was then evaporated to afford a white solid. This crude product was purified by 
column chromatography on silica gel, eluting with 40% ethyl acetate/hexane to 
afford an off white solid (477 mg, 92 % yield isolated). Molecular Formula -  
Ci6H17N 0 5S. Formula Weight -  335.38 g m ole1. Rf (EtOAc) = .10. 'H-NMR 
(CD3CN) 5: 2.39 (s, 3H, H-7’), 2.74 (m, 1H, H-3a), 2.92 (m, 1H, H-3b), 3.96 (m, 
1H, H-2), 5.88 (d, 1H, J = 8 .8 , N-H), 6.63 (d, 2H, J = 8.4, H-5, H-9), 6.92 (d, 2H, J 
= 8.4, H-6 , H-8 ) 7.25 (d, 2H, J = 8.1, H-2', H-6 '), 7.52 (d, 2H, J = 8.3, H-3', H-5'). 
13C-NMR (CD3CN) 5: 21.59 (C- 7'), 38.52 (C- 3), 58.27 (C- 2), 116.06 (C- 5, C-
9), 127.77 (C- 3', C- 5'), 128.20 (C- 4), 130.54 (C- 2', C- 6 '), 131.52 (C- 6 , C-8 ), 
138.47 (C- 4'), 144.58 (C- 1'), 156.90 (C- 7), 172.71 (C- 1).
N- [(3S) -1-oxaspiro [4.5] deca-6, 9-dien-2, 8-dion-3-yl]-4-methylbenzene 
sulfonamide (66): To a solution of 65 (177 mg, .528 mmol, 1 eq.) dissolved in 
acetone (15mL, 0 °C) was added PIFA (229 mg, .533 mmol, 1.01 eq.) in one
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portion and the resulting mixture was stirred for 45-50 minutes (confirmed by tic: 
[1:1] EtOAc/Hexane). The mixture was diluted with ethyl acetate (50 mL), then 
washed with cold water. The organic fraction was dried (M gS04) and the solvent 
evaporated to afford a Tan solid. The crude product was purified by column 
chromatography on silica gel, eluting with 50 % ethyl acetate/hexane to afford an 
off white solid (63 mg, 36 % yield isolated). Molecular Formula -  Ci6Hi5N 0 5S. 
Formula Weight -  333.359 g m ole1. XH-NMR (CDC13) 5: 2.48(s, 3H, H-7'), 4.40 
(m, 1H, H-2), 5.91 (d, 1H, J = 5.8, N-H), 6.26 (dd, 2H, J = 2, 10, H-5, H-9), 6.80 
(dd, 2H, J = 2, 10, H-6 , H-8 ), 7.33 (d, 2H, J = 8 , H-3', H-5'), 7.80 (d, 2H, J = 8.2, 
H-2', H-6 ')
(2S)-3-(4-hydroxyl-3-nitrophenyl)-2-{[(4-methylphenyl) sulfonyl] amino} 
propanoic acid 67: To a solution of 3-Nitro-L-Tyrosine (1.029 g, 4.55 mmol, 1 
eq.) dissolved in 1M NaOH (100 mL) was added a solution of tetrahydrofuran 
(150 mL) with TsCl (7.012 g, 36.9 mmol, 9.5 eq.) in three portions (5-10 min. 
apart) and the resulting orange solution was stirred vigorously at room 
temperature. After 25-30 min. the solution turned a yellow colour, indicating an 
acidic environment (pH -  3), therefore more 1M NaOH (25 mL) was added. The 
solution then returned to an orange colour, which was left to stir overnight (14-16 
hrs, confirmed by tic ([2:8] MeOH/CHCl3). The reaction mixture was acidified 
with 10% HC1 (pH 1-2, orange to yellow colour change) and extracted with
80
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
dichloromethane (lOOmL, 50 mL). The organic fractions were combined, dried 
(M gS04) and the solvent evaporated to afford a yellow solid.
The crude yellow product was then dissolved in ethanol (100 mL) and 1M 
KOH (50mL) was added. The now orange reaction mixture was warmed (80-85 0 
C) and left to stir overnight (12-14 hrs. confirmed by tic: [2:8] MeOH/CHCl3, after 
mini work up, 10 % HC1 and EtOAc). The resulting reaction mixture was cooled 
and then acidified with 10 % HC1 (pH 1-2) causing the orange solution to turned 
yellow. Then concentrated the reaction mixture and yellow precipitates formed 
which were then extracted with dichloromethane (2 x 150 mL). The organic 
fractions were combined, dried (M gS04), and the solvent was then evaporated 
leaving a yellow solid. Recrystallization in benzene and drying under vacuum 
afforded a yellow solid product (1.485 g, 8 6  % yield). Molecular Formula -  
Ci6Hi6N20 7S. Formula Weight -  380.374 g mole'1. Mpt: 137 °C. [a]D = - 58.1 0 (c: 
0.155 g 100 mL' 1 at 21 0 C). FT-IR (KBR disk) cm '1: 1734 (C 02H), 1326, 1158 
(S0 2NHR), 1539, 1430 (N 02). ^ -N M R  (CDC13) 8 : 2.40 (s, 3H, H-7’), 2.91 (m, 
1H, H-3a), 3.15 (m, 1H, H-3b), 3.74 (broad s, 1H, OH), 4.16 (m, 1H, H-2), 5.42 
(d, 1H, J = 8.5, N-H), 7.01 (d, 1H, J = 8 .6 , H-8 ), 7.20 (d, 2H, J = 8.3, H-2’, H-6 ’),
7.38 (dd, 1H, J = 2.2, 8 .6 , H-9), 7.56 (d, 2H, J = 8.3, H-3’, H-5'), 7.74 (d, 1H, J =
2.2, H-5), 10.46 (broad s, 1H, C 0 2H). 13C-NMR (CDC13) 5: 21.74 (C- 7’), 37.70 
(C- 3), 56.59 (C- 2), 120.41 (C-8 ), 125.59 (C- 5), 127.18 (C- 3', C- 5'), 127.73 (C- 
4), 129.91 (C- 2’, C- 6 '), 133.32 (C- 4'), 136.36 (C-7), 139.15 (C- 9), 144.39 (C- 
1’), 154.50 (C- 6 ), 174.65 (C- 1).
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(2E)-3-(4-hydroxyl-3-nitrophenyl) acrylic acid 69:
To a solution of 4-hydroxyl-3-nitrobenzaldehyde (1.073 g, 6.43 mmol, 1 
eq.) dissolved in pyridine (25 mL) was added piperidine (25 drops) and the 
resulting mixture was stirred (4-5 min.). Malonic acid (1.671 g, 16.1 mmol, 2.5 
eq.) was then added in one portion and the resulting mixture was warmed (60-63 
°C) and stirred overnight (12-14 hrs, confirmed by tic: EtOAc, mini work up, 10 % 
HC1 and EtOAc). The reaction was cooled and acidified (50 % HC1) until yellow 
precipitate formed (pH~2). This yellow precipitate was extracted with ethyl 
acetate (2 x 150 mL). The organic fractions were combined and washed with brine 
(150 mL), dried (M gS04), and the solvent was evaporated to afford a yellow solid. 
Removed excess solvent by vacuum and used without further purification (1.250 
g, 93 % yield). Molecular Formula -  C9H7N 0 5. Formula Weight -  209.156 g 
mole'1. FT-IR (KBR disk) cm4 : 2942 (OH), 1684 (C 0 2H), 1626 (C=C),
1533,1270 (N 02). *H-NMR (Acetone-D6) 5: 2.87 (broad s, 1H, OH), 6.58 (d, 1H, 
J= 16.0, H-2), 7.27 (d, 1H, J= 8 .8 , H-8 ), 7.70 (d, 1H, J= 16.4, H-3), 8.08 (d, 1H, J=
2.2, 8.5, H-9), 8.40 (d, 1H, J = 2.2, H-5), 10.67 (broad s, 1H, C 0 2H). The 13C-
142NMR of this compound agrees with the previously published data.
3-(3-amino-4-hydroxylphenyl) propanoic acid 70:
Detail procedure for formation of 70 can be found in experimental 
procedure of 71 and 72 below. Initial attempts to purify by recrystallization and
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column chromatography failed due to reactive qualities of product therefore used 
filtered solution of 70 directly for producing both amides 71 and 72. A small 
aliquot was used to acquire a *H-NMR of the crude product. Molecular Formula -  
C9Hn N 0 3. Formula Weight -  181.189 g m ole1. ‘H-NMR (D3C-OD) 8 : 2.46 (t,
2H, J = 7.0, H-3), 2.69 (t, 2H, J = 7.9, H-2), 6.48 (m, 1H, H-5), 6.60 (m, 2H, H-8 , 
H-9),
3-[3-(acetylamino)-4-hydroxylphenyl] propanoic acid 71:
To a solution of 69 (210 mg, 1.00 mmol, leq.) dissolved in THF (20 mL) was 
added the catalyst 10 % palladium-on-charcoal (15 % by mass, 32 mg). The 
resulting mixture was then placed on a hydrogenator, flushed (5 times) with 
hydrogen, and left to agitate under pressure (39 psi.) for 6-7 hrs. The reaction 
mixture was vented and then vacuumed filtered through Celite ® rinsing with THF 
(25-30 mL). AcCl (79 mg, 1.13 mmol, 1.13 eq.) was directly added to the filtered 
solution containing 70 and left to stir at room temperature for 60 min. Water was 
added (15 mL) and extracted with EtOAc (2 x 50 mL). The organic fractions were 
combined and washed with saturated NaCl (50mL), dried (M gS04), and the 
solvent was evaporated off. The product was re-crystallized with Hexane/Acetone 
to afford a white solid (104 mg), with a 47 % yield from compound 69. Molecular 
Formula -  C nH 13N 0 4. Formula Weight -  223.225 g mole'1. FT-IR (KBR disk) 
cm '1: 3393 (NH, OH), 1699 (C 02H), 1657 (NHAc). ^ -N M R  (CD3CN) 8 : 2.15 (s, 
3H, H-2’), 2.54 (t, 2H, J = 7.5, H-3), 2.78 (t, 2H, J = 7.5, H-2), 6.82 (d, 1H, J = 8.3,
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H-8 ), 6.95 (dd, 1H, J = 2.1, 8.3, H-9), 7.06 (d, 1H, J = 2.0, H-5), 8.53 (broad s, 1H, 
OH), 8.81 (s, 1H, NH). 13C-NMR (CD3CN) 5: 23.53 (C- 2'), 30.96 (C- 3), 35.96 
(C- 2), 119.50 (C-5), 123.04 (C- 8 ), 127.10 (C- 6 ), 127.31 (C- 9), 133.69 (C- 4), 
147.89 (C- 7), 172.09 (C-l), 174.42 (C -l’).
3-[3-(benzoylamino)-4-hydroxylphenyl] propanoic acid 72:
To a solution of 69 (222 mg, 1.06 mmol, leq.) dissolved in THF (20 mL) was 
added the catalyst 10 % palladium-on-charcoal (15 % by mass, 33 mg). The 
resulting mixture was then placed on a hydrogenator, flushed (5 times) with 
hydrogen and left to agitate under pressure (36 psi.) overnight (12 hrs) while 
recharging hydrogen pressure twice (36 psi.) until hydrogen up-take by reaction 
mixture stopped (pressure did not decrease for 1-2 hrs.). The reaction mixture was 
vacuum filtered through Celite ® rinsing with THF. To the filtered solution 
containing 70 was directly added BzCl (154 mg, 1.1 mmol, 1 eq.) and left to stir at 
room temperature for 30 min. Then 10 % HC1 (25 mL) was added and stirring 
continued an additional 5 min. followed by extraction with CH2C12 (2 x 35 mL). 
The organic fractions were combined, dried (M gS04), and evaporated off solvent. 
The resulting mixture was re-crystallized with Hexane/Acetone to afford an off 
white solid (250 mg) with an 83 % yield from compound 69. Molecular Formula -  
C 16Hi5N 0 4. Formula Weight -  285.295 g m ole1. FT-IR (KBR disk) c m 1: 3201 
(NH, OH), 1692 (C 0 2H), 1636 (NHAc). *H-NMR (Acetone-D6) 5: 2.60 (t, 2H, J = 
7.4, H-3), 2.84 (t, 2H, J = 7.9, H-2), 6.89 (d, 1H, J = 8.2, H-8 ), 7.00 (dd, 1H, J =
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2.1, 8.25, H-9), 7.57 (m, 4H, H-5, H-4', H-5', H-6 '), 8.05 (d, 2H, J = 8.2, H-3', H- 
7'), 9.07 (broad s, 1H, NH), 9.54 (broad s, 1H, OH), 10.58 (broad s, 1H, C 0 2H). 
13C-NMR (Acetone-D6) 5: 30.87 (C- 3), 36.21 (C- 2), 118.69 (C- 8 ), 123.31 (C-5), 
123.41 (C- 6 ), 126.88 (C- 9), 127.37 (C- 4), 128.54 (C-4', C-6 '), 129.61 (C-3', C- 
7'), 132.99 (C-5'), 134.99 (C-2'), 148.03 (C-7), 167.34 (C-l'), 173.94 (C-l).
N-( 1 -oxaspiro[4.5]deca-6,9-dien-2,8-dion-7-yl)acetamide (+/-)-73:
To a solution of 71 (122 mg, .547 mmol, 1 eq.) dissolved in acetone (10 mL, 0 °C) 
was added PIFA (306 mg, .711 mmol, 1.3 eq.) in one portion and stirred for 20-25 
minutes (confirmed by tic: [1:1] EtOAc/Hexane). The reaction mixture was 
diluted with ethyl acetate (15 mL), washed with cold water (10 mL), dried organic 
fraction (M gS04) and evaporated off solvent to afford a Tan solid. The crude 
product was purified by re-dissolving with CHC13, filtering of the solution through 
Celite ®, evaporating off the solvent and placing it under vacuum overnight to 
afford an off white solid (120 mg, 98 % yield). Molecular Formula -  C nH nN 04. 
Formula Weight -  221.209 g mole \  FT-IR (KBR disk) c m 1: 3333 (NH), 1777 
(lactone), 1668 (amide), 1650 (ketone), 1620 (a, [3-conjugation to ketone). 1H- 
NMR (CDC13) 6 : 2.17 (s, 3H, H-2'), 2.44 (m, 2H, H-4), 2.81 (m, 2H, H-3), 6.35 (d, 
1H, J = 10.0, H-9), 6.94 (dd, 1H, J = 3.1, 10.0, H-10), 7.75 (d, 1H, J = 3.1, H-6 ), 
7.99 (broad s, 1H, NH). 13C-NMR (CDC13) 8 : 24.86 (C- 2'), 28.36 (C- 4), 32.91 
(C- 3), 79.76 (C-5), 124.30 (C- 6 ), 127.12 (C- 9), 131.55 (C- 7), 148.37 (C-10), 
169.51 (C-l'), 175.46 (C-2), 179.40 (C-8 ).
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N-(l-oxaspiro[4.5]deca-6,9-dien-2,8-dion-7-yl)benzamide (+/-)-74:
To a solution of 71 (262 mg, .92 mmol, 1 eq.) dissolved in acetone (30 mL, 0 °C) 
was added PIFA (396 mg, .92 mmol, 1 eq.) in one portion and stirred for 20-25 
minutes (confirmed by tic: [1:1] EtOAc/Hexane). The reaction mixture was 
diluted with ethyl acetate (100 mL), washed with cold water (50 mL), dried 
organic fraction (M gS04) and the solvent was evaporated to afford a Tan solid. 
The crude product was purified by column chromatography on silica gel, eluting 
with (40) % ethyl acetate/hexane to afford an off white solid (243 mg, 8 6  % yield 
isolated). Molecular Formula -  Ci6H 13N 0 4. Formula Weight -  283.279 g mole'1. 
FT-IR (KBR disk) cm '1: 3381 (NH), 1781 (lactone), 1665 (amide), 1650 (ketone), 
1621 (a, P-conjugation to ketone). 'H-NMR (CDC13) 8 : 2.49 (m, 2H, H-4), 2.84 
(m, 2H, H-3), 6.42 (d, 1H, J = 10.0, H-9), 6.99 (dd, 1H, J = 3.1, 10.0, H-10), 7.54 
(m, 3H, H-4', H-5', H-6 '), 7.86 (m, 2H, H-3', H-7'), 7.95 (d, 1H, J = 3.1, H-6 ), 8.81 
(broad s, 1H, NH). 13C-NMR (CDC13) 5: 28.40 (C- 4), 33.02 (C- 3), 79.84 (C- 5),
124.54 (C-6 ), 127.20 (C- 9), 127.32 (C- 4', C- 6 '), 129.16 (C- 3', C- 7'), 131.74 (C- 
7), 132.72 (C-5’), 133.87 (C-2’), 148.60 (C-10), 166.21 (C-l'), 175.44 (C-2).
N- [(l'S, 2R, 6 ’R)-5,5'-dioxo-4, 5-dihydro-3H-spiro [furan-2, 2 ’-[7] oxabicyclo 
[4.1.0] kept [3] en]-4'-yl] benzamide 76: To a solution of (+/-)-74 (55mg, .14 
mmol, 1 eq.) dissolved in 3:1 THF/H20  (4 mL, 0 °C) was added ~ 30 % H20 2 (200 
pL, 67 mg, 2 mmol, 14 eq.) and stirred (6  hrs, confirmed by tic: [1:1]
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EtOAc/Hexane). The reaction mixture was diluted with water (15 mL) and 
extracted with ethyl acetate (2 x 25 mL). The organic fractions were combined, 
dried (M gS04), and evaporated solvent to afford a solid. The crude product was 
purified by column chromatography on silica gel, eluting with 50 % ethyl 
acetate/hexane to afford an off white solid. The resulting mixture was triturated 
with HPLC hexane to remove some impurity (3 mg, 7 % yield). Molecular 
Formula -  Ci6Hi3N 0 5. Formula Weight -  299.278 g mole'1. ‘H-NMR (CDC13) 5: 
2.48 (t, 2H, J = 8.4, H-3), 2.85 (m, 2H, H-4), 3.72 (d, 1H, J = 4, H-7), 3.77 (m, 1H, 
H-6 ), 7.54 (m, 3H, H-4', H-5', H-6 '), 7.72 (d, 1H, J = 2.7, H-10), 8.35 (broad s, 1H, 
NH). 13C-NMR (CDC13) 6 : 27.92 (C- 4), 33.02 (C- 3), 51.47 (C- 6 ), 55.37 (C-7),
81.54 (C- 5), 123.89 (C- 9), 127.26 (C- 4', C- 6 '), 129.01 (C- 3', C- 7'), 129.20 (C-
1 0 ), 132.81 (C-5'), 133.75 (C-2 '), 166.28 (C -l’), 174.86 (C-2 ), 188.18 (C-8 ).
(2S)-3-(3-amino-4-hydroxylphenyl)-2-{[(4-methylphenyl) sulfonyl] amino} 
propanoic acid 77: Initial attempts to purify by recrystallization and column 
chromatography failed due to reactive qualities of product therefore used filtered 
solution directly for producing the amide 78. A small reaction was repeated to 
acquire a 1 H-NMR for analytical information of the crude product (see 
experimental procedure of 78 below). Molecular Formula -  Ci6Hi8N20 5S.
Formula Weight -  350.391 g mole'1. 'H-NMR (D20  + Na2C 0 3) with a trace of 
EtOH solvent, 8 : 2.35 (s, 3H, H-7'), 2.45 (m, 1H, H-3a), 2.78 (m, 1H, H-3b), 3.59
87
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
(m, 1H, H-2, EtOH), 6.33 (m, 3H, H-5, H-8, H-9), 7.22 (d, 2H, J = 8.6, H-3', H-5'),
7.39 (d, 2H, J = 8.3, H-2', H-6').
(2S)-3-[3(acetylamino)-4-hydoxylphenyl]-2-{[(4-methylphenyl) sulfonyl] amino} 
propanoic acid 78: To a solution of 67 (166 mg, .437 mmol, leq.) dissolved in 
THF (25 mL) was added the catalyst 10 % palladium-on-charcoal (15 % by mass, 
26 mg). The resulting mixture was then placed on a hydrogenator, flushed (5 
times) with hydrogen and left to agitate under pressure (39 psi.) for 15-16 hrs. The 
reaction mixture was vented and then vacuumed filtered through Celite ® rinsing 
with THF (25-30 mL). To the filtered solution containing 77 was directly added 
AcCl (51 mg, .6 6  mmol, 1.5 eq.) and left to stir at room temperature overnight.
The reaction mixture was diluted with CH2CI2 (50 mL), washed with saturated 
NaCl (15 mL), dried (M gS04) and evaporated off solvent. It was then re­
crystallized with Hexane/Acetone to afford a white solid (6 8  mg), with a 40 % 
yield from compound 67. Molecular Formula -  C18H2oN20 6S. Formula Weight -  
392.427 g m ole1. [a]D = - 88.9 0 (c: 0.018 g 100 m L 1 at 21 0 C). FT-IR (KBR 
disk) cm '1: 3257 (NH), 1777 (C 0 2H), 1657 (amide), 1289, 1157 (S 0 2). !H-NMR 
(Acetone-D6) and a trace of EtOAc solvent, 8 : 2.20 (s, 3H, H-2"), 2.38 (s, 3H, H- 
7'), 2.83 (m, 1H, H-3a), 2.93 (m, 1H, H-3b), 4.04 (m, 1H, H-2, EtOAc), 6.64 (d, 
1H, NH-2), 6.70 (d, 1H, J = 8.2, H-8 ), 6.83 (dd, 1H, J = 2.1, 8.2, H-9), 7.15 (broad 
s, 1H, H-5), 7.25 (d, 2H, J = 7.9, H-2', H-6 ’), 7.55 (d, 2H, J = 8.3, H-3', H-5'), 9.25 
(broad s, 1H, C 0 2H). 13C-NMR (Acetone-D6) 6 : 21.48 (C- 2"), 23.50 (C- 7'), 37.70
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(C- 3), 58.29 (C- 2), 118.97 (C-5), 123.04 (C- 8 ), 127.30 (C- 6 ), 127.73 (C- 3', C- 
5'), 127.87 (C- 9), 128.72 (C- 4'), 130.25 (C- 4, C- 2', C- 6 '), 139.11 (C- 1"),
143.80 (C-l'), 148.34 (C- 7), 172.61 (C- 1).
N- ((3S)-3-{[(4-methylphenyl) sulfonyl] amino}- 1-oxaspiro [4.5] deca-6, 9-dion-2, 
8-dien-7-yl) acetamide (+)-79: To a solution of 78 (118 mg, .30 mmol, 1 eq.) 
dissolved in acetone (20 mL, 0 °C) was added PIFA (142 mg, .331 mmol, 1.1 eq.) 
in one portion. After confirming reaction completion by tic (25 min.), the reaction 
mixture was diluted with EtOAc (25 mL), washed with cold water (15 mL), dried 
solvent (M gS04) and evaporated off solvent. The crude product was purified by 
column chromatography on silica gel, eluting with 50 % ethyl acetate/hexane to 
afford the major and minor diastereomer as white solids. The resulting mixture 
was triturated with HPLC hexane to remove most of the impurity. Isolated 38 mg 
of the major diastereomer, 54 mg of a mixture of the major and minor 
diastereomer and 8 mg of the minor diastereomer (100 mg total, 85 % total yield). 
Analytical information is reported for major diastereomer plus 79. Molecular 
Formula -  Ci8H 18N20 6S. Formula Weight -  390.410 g mole'1. [a]D = + 55.6 0 (c: 
0.036 g 100 mL' 1 at 22 0 C). FT-IR (KBR disk) cm'1: 3327 (NH), 1778 (lactone), 
1654 (amide), 1645 (ketone), 1631 (a, p-conjugation to ketone), 1339, 1161 (S 02). 
1 H-NMR (CD3CN) trace of acetone solvent, 6 : 2.16 (s, 3H, H-7'), 2.28 (m, 1H, H- 
4a), 2.45(s, 3H, H-2"), 2.46 (m, 1H, H-4b), 3.54 (m, 1H, H-3), 6.12 (d, 1H, J = 8.0, 
NH-2), 6.25 (d, 1H, J = 10.0, H-9), 7.06 (dd, 1H, J = 3.1, 10.0, H-10), 7.38 (d, 2H,
89
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
J = 8.0, H-2’, H-6'), 7.52 (d, 1H, J = 3.1, H-6), 7.78 (d, 2H, J = 8.3, H-3', H-5’), 
8.18 (broad s, 1H, NH-7). 13C-NMR (CD3CN) 5: 21.59 (C- 2"), 24.72 (C- 7’), 
39.96 (C- 4), 52.97 (C- 3), 78.42 (C-5), 124.78 (C- 6), 127.48 (C- 9), 127.95 (C- 
3', C- 5’), 130.84 (C- 2', C- 6’), 133.51 (C- 7), 138.81 (C- 4’), 145.16 (C -l’), 147.41 
(C- 10), 170.93 (C- 1"), 173.63 (C- 2).
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NMR Spectra of Compounds in Numerical Order
(All values are in ppm)
Appendix 1
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^-N M R  Spectrum of Compound 65
OH
I
8 ^ 7<^ 6
II I
H
O//
.1:
/ /
o
'1' 5'
HO ^O
^ 6 -  
k  'I
vCH3
7'
94
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
13C-NMR Spectrum of Compound 65
OH
I
8/7 < ^6
H
3\  \N V / ?
f
H O ^ O  Jlx
3 "CH3
7'
1— 1B0 —I— 160 ~T—140 —1— 120 100 —T~80 ~T~60 40 20
95
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
COSY-NMR Spectrum of Compound 65
OH
I
8/ 7 ^ 6  
II I
9^ 4 ^ 5 H
3 \  x N v  '9^O  C ft1
I // ^ 1 '^  ^5'
0  I I 
HO v O 2'^ s. 
3 v CH3
7'
w-r.; r//
w U L
D
1
1 1 1 1 1 1 1 1TTT
-2
-4
-6
r ppm
96
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
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!H-NMR Spectrum of Crude Compound 70
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COSY-NMR Spectrum of Compound 72
6 '
OH Hi ' l l
7 n y
O ^ O H
O
*
p in  i n 111 M m  i m  11
r 2
r 6
r 0
E -io
: ppm
1 1 1 1 r i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 i i 1 1 i t t  
ppm 10 8
111
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
COSY-NMR Spectrum of Compound 72
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‘H-NMR Spectrum of Compound (+/-)-74
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‘H-NMR Spectrum of Compound (+/-)-76
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^ -N M R  Spectrum of Compound (+/-V76
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DEPT-135-NMR Spectrum of Compound (+/-V76
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1H-NMR Spectrum of Compound 77
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'H-NMR Spectrum of Compound 78
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'H-NMR Spectrum of Compound (+1-79, Major Diastereomer
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13C-NMR Spectrum of Compound (+)-79, Major Diastereomer
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DEPT-NMR Spectrum of Compound (+)-79, Major Diastereomer
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HETCOR-NMR Spectrum of Compound (+)-79, Major Diastereomer
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HETCQR-NMR Spectrum of Compound (+)-79, Major Diastereomer
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^ -N M R  Spectrum of Crude Product (+)-79/80, Diastereomers
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^ -N M R  Spectrum of Crude Product (+V79/80, Diastereomers
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‘H-NMR Spectrum of Crude Product f+)-79/80, Diastereomers
h3c -
7'
2' O 0
-4 \  i! t\  /  ~S -N H
8
— i—  
7.69
T 7. M?70 7.60
132
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
^ -N M R  Spectrum of Crude Product (+)-79/80, Diastereomers
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^ -N M R  Spectrum of Crude Product (+V79/80, Diastereomers
---------------------- !------------------------- j------------------------ j------------------------- 1—
ppm 6.35 6.30 6.25 6.20
134
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
A Table of Manumycin Structures 7’11 
Appendix 2
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Compound R1 R2
Type I-a
Alisamycin
V 0 OH
Ent-alisamycin 0 o ^ 7
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